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ABSTRACT 
Background & Aims: Lynch syndrome (LS) is an autosomal dominant disorder and is 
caused by mutations in one of the DNA mismatch repair (MMR) genes, in particular, 
MLHJ, MSH2, MSH6 and PMS2. Lynch syndrome mutation carriers are at a high risk of 
developing colorectal cancer (CRC) and gynecological cancers, and as such, targeted 
screening programs have been developed. The primary objective of this thesis was to 
determine the phenotypic expression of three different MSH2 mutations causing LS in 
Newfoundland and to examine the impact of screening in this group of MSH2 mutation 
earners. 
Methods: Age to onset of first CRC, first extracolonic cancers and death were compared 
for those with an intron 5 splice site mutation, an exon 8 deletion and an exon 4-16 
deletion. To determine the impact of colonoscopic screening in male and female MSH2 
mutation carriers, CRC incidence and survival in the screened group was compared to 
that expected, derived from the non-screened group. To correct for survivor bias controls 
were matched for age at entry into screening and also for gender. Compliance with 
screening recommendations of colonoscopy every 1-2 years was also addressed. 
Gynecological cancer incidence and overall survival was compared in females who 
received gynecological screening and in matched controls. Controls were randomly 
selected from non-screened mutation carriers who were alive and disease-free at the age 
the case entered the screening program. One matched control was selected for each case. 
II 
Results: For all three mutations males had a higher age-related risk of CRC and death 
compared to females. For the intron 5 splice site mutation carriers, the number of 
transitional cell cancers of the urinary tract was significantly lower and time to first 
ovarian cancer was significantly higher than in the carriers of the genomic deletions. 
Median age to CRC was 58 years in males who received colonoscopic screening whereas 
expected was 47 years (P< .OOOl), and median survival in screened males was 66 years 
compared to expected of 62 years (? =.034) . In females, median age to CRC in the 
colonoscopic screened group was 79 years, whereas in the non-screened group it was 57 
years (P=.OOO), and median survival was 80 years in the screened group compared to 
expected of63 years (P= .OOl). Eight of41 (20%) males and five of 68 (7%) females who 
had serial screening colonoscopies developed an interval CRC within 2 years of previous 
colonoscopy. Endometrial or ovarian cancer occurred in 14 of 54 (26%) women in the 
gynecological screened group. Median age to diagnosis of gynecological cancer was 54 
years in the screened group compared to 56 years in matched controls (p=.50). Stage I or 
II cancer was diagnosed in 92%.of screened patients compared to 7 1% in the control 
group (?= .1 7). Mean survival in the screened group was 79 years compared to 69 years 
in the matched control group (P=.ll ), likely associated with concomitant colonoscopic 
screen mg. 
Conclusions: The incidence of C RC in MSH2 mutation carriers, exposed to the same 
environment, is not modified by the specific mutation, although there is a suggestion that 
type of mutation may influence development of some extracolonic cancers. For both 
Ill 
males and females, colonoscopic screening was associated with decreased CRC risk, later 
age of onset, and better survival than expected if non-screened, however, CRCs 
continued to occur. CRC development may be further reduced by decreasing the 
screening interval to one year in MSH2 mutation carriers and improving compliance and 
quality of colonoscopic examination. Gynecological screening did not result in earlier 
gynecologic cancer detection and despite screening two young women died from ovarian 
cancer suggesting that prophylactic hysterectomy with bilateral salpingo-oophorectomy 
be considered in female mutation carriers who have completed childbearing. 
IV 
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CHAPTER 1 
Outline 
1.1 OUTLINE 
Lynch syndrome (LS) is characterized by autosomal dominant inheritance, early age at 
onset of colorectal carc inoma, right-sided predominance, and increased incidence of 
synchronous and metachronous colorectal cancers (CRCs). Additionally, extra-colonic 
cancers of the endometrium, ovaries, gastrointestinal tract, genitourinary tract, bi liary 
tract, panc reas and brain are frequently observed. Lynch syndrome shows incomplete 
penetrance (not all mutation carriers will develop a cancer) and variable expressivity 
(indiv iduals develop different cancers at different ages) leading to phenotypic 
heterogeneity. Genetic heterogeneity is also a feature of LS as mutations in at least four 
di fferent mismatch repair (M M R) genes are responsible for LS. 
Chapter 2 provides a general overview of the different aspects of LS. History , cl inical 
features, cancer risks, diagnostic strategies, molecular genetics, screening and 
management of LS are all discussed. 
Chapter 3 compares the phenotypic expression of three different founder MSH2 
mutations causing LS . The cumulative risk of CRC, extracolonic cancers and death was 
compared fo r MSH2 mutation carri ers with an intron 5 splice site mutation, an exon 8 
de letion and an exon 4-1 6 deletion. Gender re lated risks for LS-associated cancers and 
death, were also measured. 
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Chapter 4 looks at the impact of colonoscopic screening in MSH2 mutation carriers with 
one of three different founder MSH2 mutations described in Chapter 3. This study 
evaluated the effectiveness of colonoscopic screening for male and female mutation 
carriers. Incidence of CRC and survival in the screened group was compared to that 
expected, derived from the non-screened group, and adj usted for survivor bias. 
Additionally, compliance with colonoscopic screening recommendations and 
appropriateness of the screening interval were addressed . 
The impact of gynecological screening in LS is discussed in Chapter 5. The 
effectiveness of gynecological screening was evaluated for females belonging to families 
with one of the three MSH2 mutations described in Chapter 3. Incidence of gynecological 
cancer and overall survival was compared for those who were screened (cases) and for 
matched controls, who were alive and disease-free at the age the case entered the 
screenmg program. 
Chapter 6 provides a general discussion of the thesis. The impact of screening in MSH2 
mutation carriers, the study limitations and the barriers to effective disease management 
are discussed. The benefits of this study and future directions are also detailed. A 
summary of the research findings and a list of recommendations are presented in 
Chapter 7. 
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CHAPTER2 
Lynch Syndrome 
4 
2.1 INTRODUCTION 
Colorectal Cancer (CRC) is a major public health problem in the Western world. In 
Canada, CRC is the third most common cancer, after prostate and lung in men and after 
breast and lung in women, and is the second and third most common cause of cancer-
related death for males and females, respectively. Newfoundland and Labrador has the 
highest CRC incidence rates among men and women in Canada [Canadian Cancer 
Society's Steering Committee 2011] and the highest incidence of inherited CRC in the 
world [Green 2007]. 
Colorectal cancer is a common and heterogeneous disease that is influenced by both 
environmental and genetic factors. The majority of CRC cases are sporadic and account 
for approximately 70% of the CRC burden. Kindred and twin studies have estimated that 
the remaining 30% of CRC cases are an inherited form of the disease [Lichtenstein 2000; 
Zeegers 2008]. Inherited CRC can be divided into famil ial and hereditary CRC cases, 
with approximately 15-20% being familial and 5- 10% being hereditary [Lynch 2006; 
Jasperson 201 0]. Familial cases have an increased risk of CRC due to positive family 
history of CRC but do not meet criteria for known hereditary CRC syndromes. This risk 
is dependent on the number of affected relatives and their age at diagnosis. The molecular 
etiology of familial CRC remains poorly understood but is likely caused by alterations in 
single genes that are less penetrant but more prevalent than genes causing hereditary 
CRC [Jasperson 20 I 0] . Hereditary cases have an increased risk due to an inherited 
susceptibility to CRC and show extensive phenotypic and genotypic heterogeneity. The 
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majority of hereditary CRC cases are associated with one of two well-defined inherited 
syndromes: Lynch syndrome (LS) and fami lial adenomatous polyposis (F AP). 
Lynch syndrome, often called hereditary non-polyposis colorectal cancer (HN PCC), is 
the most common hereditary CRC syndrome and is responsible for approximately 2 to 5 
percent of all CRC cases [de Ia Chapelle 2005; Hampel 2005a, 2008; Lynch 2009a] and 
similarly is responsible for about 2 percent of all endometrial cancers [Hampel 2006; 
Kehoe 2007]. Lynch syndrome is an autosomal dominant condition caused by mutations 
in DNA mismatch repair (MMR) genes and is characterized by early onset CRC and an 
increased risk of malignancy for extracolonic cancers. Familial adenoma to us polyposis is 
the second most common inherited syndrome and accounts for approximately 1% of the 
total CRC burden. Patients with F AP develop hundreds to thousands of colonic adenomas 
beginning in early adolescence and show close to 100% lifetime risk for CRC without 
prophylactic management. Attenuated fami lial adenomatous polyposis (AF AP) is a less 
severe form of the disease, characterized by fewer ( < 1 00) adenomatous polyps of the 
colon and a reduced li fetime risk for CRC (- 70%). Both FAP and AFAP are autosomal 
dominant disorders caused by inactivating mutations of the adenomatous polyposis coli 
(APC) gene [Jass 2008; Jasperson 201 0]. Other rare inheri ted conditions causing CRC are 
MUTYH-associated polyposis (MAP), hamartomatous polyposis syndromes, namely 
Peutz-Jeghers syndrome and juvenile polyposis syndrome, and hyperplastic polyposis 
syndrome (HPS). MUTYH-associated polyposis is caused by mutations in the MUTYH 
gene and is inherited as an autosomal recessive condition, hamartomatous polyposis 
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syndromes are caused by germline mutations in STKJJ, SMAD4 and BMPRJA and the 
etiology of HPS is unknown [Jass 2008]. A precise understanding of the genetics of 
inherited CRC is important for identifying at-risk individuals so that targeted cancer 
prevention strategies can be implemented to improve patient outcomes. 
2.2 HISTORY OF LYNCH SYNDROME 
In 191 3, A.S. Warthin published a large pedigree with numerous cases of CRC along 
with cases ofuterine and stomach cancer [Warthin 1913]. This fam ily was designated as 
'cancer Family G '. Family G was updated numerous times over the years, again by 
Warthin in 1925 [Warthin 1925], and by two of his colleagues, Weller and Hauser, in 
1936 [Hauser 1936]. In 1966, Lynch eta!. described two additional families , families N 
and M, whose tumor spectrum was very similar to Family G [Lynch 1966]. In 1971 , 
Lynch revisited family G [Lynch 1971] , and along with families Nand M, characterized 
the syndrome, which was later referred to as ' Lynch syndrome ' . 
In 1989, the International Collaborative Group on Hereditary Nonpolyposis Colorectal 
Cancer (ICG-HNPCC) was established to promote international research on the genetic, 
clinical and pathologic aspects of LS [Lynch 2005]. At this time, LS was largely 
unknown and the group proposed a new name for the syndrome, hereditary non-polyposis 
colorectal cancer syndrome (HNPCC), explaining which tumor is mainly involved in the 
disease [Vasen 1991 , 2007a]. It was thought that such a name might promote the 
recognition of the syndrome. As the syndrome became more well-defined and well-
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known, and with the identification of MMR mutations in this syndrome, it was decided 
that the term 'hereditary nonpolyposis colorectal cancer' was no longer ideal and the term 
' Lynch syndrome' was reintroduced [Vasen 2007a]. Lynch syndrome refers to the 
autosomal dominant disease caused by germ line mutations in one of the DNA MMR 
genes [Boland 2005]. The name hereditary nonpolyposis colorectal cancer syndrome can 
still be given to disorders that have similar phenotypes and meet the Amsterdam criteria 
(a set of clinical criteria developed for standardizing the diagnosis of LS) but who do not 
have a known DNA MMR defect [e.g., familial colorectal cancer type X (FCCTX)] 
[Lynch 2009b]. 
2.3 CLINICAL FEATURES OF LYNCH SYNDROME 
Lynch syndrome is an hereditary colon cancer syndrome and is caused by germline 
mutations in DNA MMR genes, in particular MLHJ, MSH2, MSH6, and PMS2 [Wheeler 
2000; Lynch 2003; Peltomaki 2004]. Mutations in MSH2 and MLHJ account for 
approximately 90% of LS cases, mutations in MSH6 account for approximately 10% and 
mutations in PMS2 are rare ly detected [Peltomaki 2004; Jasperson 20 10]. 
Lynch syndrome is an autosomal dominant inherited syndrome with incomplete 
penetrance and a variable phenotype with respect to tumor site and age at onset. Table 
2.1 lists the clinical characteristics of LS. Individuals with LS develop early onset CRC at 
an average age of 45 years. The tumors are mainly located in the proximal colon and 
there is an increased incidence of synchronous and metachronous CRCs. Synchronous 
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tumors are defined as secondary primary tumors detected at the time of diagnosis or 
occurring within the first six months of diagnosis of the first primary cancer. 
Metachronous tumors, however, are diagnosed more than six months after the first 
primary. Mutation carriers are also at an increased risk of extracolonic cancers, especially 
cancer of the endometrium, and may be at risk for associated malignancies of the brain 
(glioblastomas) in the Turcot ' s syndrome variant of LS, and skin (sebaceous gland 
adenomas, carcinomas, or keratoacanthomas) in the Muir-Torre syndrome variant ofLS. 
Colorectal tumors in LS often show specific pathological characteristics, such as poor 
differentiation with mucoid features and signet cell excess, Crohn' s-like reaction, and an 
excess of tumor infiltrating lymphocytes [Jass 2004, Lynch 2008b ], and the majority 
exhibit microsatellite instability (MSI), a feature of cancers that arises in the setting of 
defective MMR genes [Jasperson 20 10]. The adenoma to invasive carcinoma sequence is 
accelerated in LS, however survival, when controlled for age and stage, is improved 
compared to sporadic CRC in the general population [Watson 1998]. Knowledge of these 
clinical features is essential for understanding LS and can be used effectively for 
diagnosis, screening, management and ultimately cancer prevention [Lynch 2008a, 
2009a]. 
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Table 2.1 Clinical features of Lynch Syndrome [Lynch 2008a, 2009a] 
• Autosomal Dominant: Autosomal dominant inheritance pattern 
• Early age at Diagnosis: Earlier average age at onset of CRC compared to the general 
population ( 45 years versus approximately 65 years) 
• Right-sided Predominance: Proximal (right-sided) CRC involvement (70-85% of 
CRCs arise proximal to the splenic flexure) 
• Synchronous & Metachronous CRCs: High risk of synchronous and metachronous 
CRCs (25-30% of patients develop a second primary CRC within 10 years oftheir 
surgical resection for initial CRC if they received a less than subtotal colectomy) 
• Extracolonic Cancers: Increased risk of extracolonic cancers [namely cancers of the 
endometrium, ovaries, stomach, small bowel, pancreas, hepatobiliary tract, upper uro-
epithelial tract (transitional cell carcinoma of the ureter and renal pelvis), and brain (in 
the Turcot syndrome variant of Lynch syndrome)] 
• Associated Malignancies: Other associated malignancies (sebaceous adenomas, 
sebaceous carcinomas and multiple keratoacanthomas in the Muir-Torre syndrome 
variant of Lynch syndrome) 
• Tumor Characteristics: CRC tumors in LS show a pathology that is more often poorly 
differentiated, with an excess of mucoid and signet-cell features, show a Crohn-like 
reaction and contain a significant excess of infi ltrating lymphocytes within the tumor 
• Better Survival: Improved survival from CRC in LS as compared to sporadic CRC in 
the general population 
• Shorter Adenoma to Carcinoma Sequence: Accelerated carcinogenesis (adenomas 
can develop into carcinoma within 1-2 years in Lynch syndrome compared with 8-1 0 
years in the general population) 
• Microsatellite Instability : High frequency of microsatellite instability in CRC tumors 
(approximately 90% ofLS tumors exhibit MSI) 
• MMR Mutation: Identification of a germline mutation in a MMR gene (MLHJ , MSH2, 
MSH6, and PMS2) 
2.3.1 Cancer Risks in Lynch Syndrome 
An accurate estimation of CRC and extracolonic cancer risk for mutation carriers is 
essential for genetic counseling and the development of appropriate screening programs. 
Several studies have evaluated the cancer risks in LS [Vas en 1996, 200 1; Dunlop 1997; 
Lin 1998 ; Aarnio 1999; Froggatt 1999; Hendricks 2004; Hampel 2005b; Quehenberger 
2005 ; Barrow 2008; Senter 2008; Watson 2008, 2009; Kopciuk 2009; Ramsoekh 2009]. 
10 
The most efficient way to calculate these risks would be to use a cohort of proven 
mutation carriers, however, many risk estimates provided in the literature are based on 
proven and presumed mutation carriers. Also, risk estimates may be biased due to the 
way families were ascertained. The majority of early studies included fam ilies who met 
the Amsterdam criteria or included high risk families referred to clinical genetics 
departments. Therefore, families without an apparent clustering of CRC due to small 
sibships, few cancer cases, unrelated deaths, non-paternity, adoption or insufficient 
pedigree information, were Jess frequently included. Analysis ofthis high risk group 
results in an overestimation of the cumulative cancer risks [Barrow 2009]. A few studies 
have attempted to correct for ascertainment bias using different evaluation models and 
have found lower risk estimates than previously reported [Carayol 2002; Quehenberger 
2005]. 
Lifetime risk of LS cancers varies considerably due to the numerous ways in which risk 
estimates are calculated. Some studies report risks associated with particular genes while 
others present combined risk estimates. The lifetime risk of CRC in mutation carriers 
ranges from 15-100% (Table 2.2) and is dependent on gender, method of ascertainment 
and the MMR genes involved. Male carriers in a ll four MMR mutations are at an 
increased risk of developing CRC compared to female mutation carriers . The lifetime risk 
for endometrial cancer is also very high and ranges from 15-7 1%. For other LS-related 
cancers, the lifetime risk ranges anywhere from 1-32% and is highest for urinary tract, 
ovarian and gastric cancers (Table 2.2). 
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Table 2.2 Lifetime risk of cancer in Lynch Syndrome 
Affected Mismatch Repair Gene 
Cancer Type MLHIIMSH2* MLHJ MSH2 MSH6 
Colorectal cancer 
Male 27-100 58-94 53-96 
Female 22-83 50-63 39-68 
Endometrial cancer 28-60 19-42 24-61 
Ovarian cancer 6-14 3-6 8-21 
Gastric cancer 9-13 2-1 I 4-8 
Small bowel cancer 3 5-7 1-5 
Urinary tract cancer 3-4 1-3 4-32 
Biliary tract cancer 1-2 3 0.4 
Brain 3-4 1-6 
*Lifetime risk for MLH1 and MSH2 mutation carriers combined 
36-69 
18-30 
49-71 
NA 
10 
NA 
NA 
NA 
NA 
PMS2 
20 
15 
15 
NA 
NA 
NA 
NA 
NA 
NA 
Lifetime risk estimates based on the studies of Vasen 1996, Dunlop 1997, Lin 1998, 
Aarnio 1999, Froggatt 1999, Vasen 200 1, Hendricks 2004, Hampel 2005b, Quehenberger 
2005, Barrow 2008, Senter 2008, Watson 2008, Barrow 2009, Kopciuk 2009, Ramsoekh 
2009. 
Several studies have reported differences in the clinical cancer phenotype between MMR 
mutations. Carriers of MSH2 mutations may be at an increased risk of developing 
extracolonic cancers compared to individuals with MLH1 mutations [Lin 1998; Vasen 
200 1] and may also have an increased incidence of Muir-Torre syndrome. MLH 1 carriers 
may have an increased lifetime risk of developing CRC when compared with carriers of 
MSH2, MSH6 and PMS2 mutations [Lynch 2006, 2008a]. The mean age at onset ofCRC 
in MLH1 and MSH2 mutation carriers is approximately 45 years. For carriers of MSH6 
and P MS2 mutations, the mean age at diagnosis of CRC is delayed by 5-l 0 years and 15 
years, respectively [Plaschke 2004; Senter 2008; Ramsoekh 2009]. MSH6 mutation 
carriers show a lower expression of CRC when compared to MLH 1 and MSH2 mutation 
carriers but have an increased lifetime risk of developing endometrial cancer [Hendricks 
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2004; Barrow 2009; Ramsoekh 2009]. Carriers of PMS2 mutations have a substantially 
reduced risk of developing CRC or endometrial cancer compared to other MMR mutation 
carriers [Senter 2008]. 
2.3.2 CRC Survival in Lynch Syndrome 
Several studies have looked at the survival of patients with LS-associated CRC compared 
to sporadic CRC. A Finnish study compared the survival of 175 patients with suspected 
LS to a population based cohort of over 14,000 patients with apparentl y sporadic CRC 
diagnosed at less than 65 years [Sankila 1996]. The overall 5-year cumulative survival 
rate was found to be 65% for patients with LS compared to 44% for patients wi th 
sporadic colorectal cancer. A further analysis of those with a confirmed MLHJ germline 
mutation (the rest were diagnosed by the Amsterdam criteria) revealed an even larger 
survival advantage over those with sporadic CRC. This survival advantage for LS 
patients compared to sporadic CRC patients was found in every strata studied and was 
not due to a screening advantage for LS patients. After adjustment for stage at diagnosis, 
the survival rates were still better among patients with localized (Dukes' A & B) (85% 
for LS versus 68% for sporadic) and non-localized (Dukes' C & "D") (40% for LS versus 
18% for sporadic) tumors, disproving the view that the good prognosis observed in 
patients with LS-associated CRC is due to a more favorable stage at diagnosis. 
In 1997, a Danish study evaluated CRC tumor parameters and survival in LS [Myrhoj 
1997] . They compared 108 individuals fulfilling the Amsterdam criteria to 870 
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individuals with sporadic CRC diagnosed at less than 40 years. LS-associated CRC was 
found to behave differently than sporadic CRC with more right sided carcinomas (68% 
versus 49%), more synchronous (7% versus 1 %) and metachronous (29% versus 5%) 
lesions, more localized carcinomas (Dukes' A and B) (62% versus 39%) and a 
significantly higher crude 5-year survival rate (56% versus 30%). The metastatic 
tendency was less in LS-associated CRC than sporadic CRC and survival was 
substantially better in LS patients compared to young sporadic patients. However, after 
stratification into localized carcinomas (Dukes' A & B) and those with regional lymph 
node metastases (Dukes' C), they found the crude 5-year survival rate only differed 
significantly between those with Dukes' C carcinomas. The survival rates for localized 
tumors were 69% and 66%, respectively, for LS patients versus sporadic patients, and for 
Dukes ' C carcinomas it was 6 1% versus 21% (p<0.01). 
Watson et al. [Watson 1998] compared stage and survival in a retrospective cohort of LS 
family members with CRC to an unselected hospital series of patients with sporadic 
CRC. Previous work had shown LS-associated CRC to have a better prognosis than 
sporadic CRC but it had been unclear whether this could be due to differences in stage at 
diagnosis. Two hundred and seventy four individuals, who met either the Amsterdam 
criteria or were known to carry an MMR mutation, were compared to 820 consecutive 
individuals with sporadic CRC. LS CRC cases were found to have significantly lower 
stage disease at diagnosis than sporadic CRC cases, due mainly to the fact that distant 
metastases at diagnosis were rare in LS. In stage-stratified survival analysis, LS cases 
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were found to have a significant overall survival advantage over sporadic cases regardless 
of adjustment for their younger age (HR=0.63 ; p<0.002). 
2.3.3 Gynecological Cancer Survival in Lynch Syndrome 
Various studies have shown that LS-associated CRC has better survival estimates than 
corresponding sporadic CRC [Sankila 1996; Myrhoj 1997; Watson 1998]. Similarly, 
work has been done to determine whether the survival rate of patients with gynecological 
cancer due to LS differs from sporadics. 
Boks et al. [Boks 2002] compared the survival rates of LS-associated endometrial cancer 
with sporadic endometrial cancer. The study group involved 50 women with a germline 
mutation or who met the Amsterdam Criteria II . These women were matched for age at 
diagnosis and FIGO stage to 100 controls with sporadic cancer. The majority of study 
patients (78%) presented with stage I cancer. The overall 5-year cumulative survival rates 
(88% vs. 82%) and the tumor histologic subtypes were found to be similar for women 
with LS and for matched controls suggesting a likeness in the biological behavior of LS-
associated and sporadic endometrial cancer. 
Conflicting results have been published regarding LS-associated ovarian cancer survival 
compared to sporadic ovarian cancer. Crijnen et a!. [Crijnen 2005] compared the survival 
of patients with ovarian cancer due to LS with a control group matched for age (age +/- 5 
years), stage at diagnosis (FIGO stage) and year of diagnosis (diagnosis year +/- 5 years). 
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For cases diagnosed before 1970, the difference in year of diagnosis was somewhat 
larger. Twenty six women that met either the Amsterdam II criteria or who had an MMR 
gene mutation identified were compared to 52 controls from a population-based registry. 
The mean age at diagnosis was significantly lower for LS-associated ovarian cancer 
compared to all cases of ovarian cancer in the registry (50 vs. 61 ) . Also, when compared 
to all cases in the registry, significantly moreLS-associated ovarian cancers were 
diagnosed at an early stage (I or II) (77% vs. 39%). None of the stage I cases were 
detected by screening, hence early detection cannot explain this finding. This study 
found that the overall cumulative 5-year survival rate was simi lar for both LS-associated 
ovarian cancer and sporadic ovarian cancer (64.2% vs. 58. 1 %), suggesting a likeness in 
the biological behavior of ovarian cancer due to LS and sporadic ovarian cancer. 
More recently, a study by Grindedal et al. [Grindedal 20 I 0] described ovarian cancer 
survival in carriers of pathogenic mutations in one of the MMR genes. One hundred and 
forty-four mutation carriers were compared to both BRCA-associated and sporadic 
ovarian cancer cases. Ten year survival specific for deaths due to ovarian cancer was 
found to be 81% for MMR mutation carriers compared to only 36%-4 7% for BRCA 
mutation carriers and the general population. However, 80% of ovarian cancers 
diagnosed in MMR mutation carriers were found to be stage I or II contrasting with the 
more than two thirds of ovarian cancer cases diagnosed as stage III or IV in BRCA-
associated and sporadic ovarian cancer. Again this low stage at diagnosis for LS-
associated ovarian cancer could not be explained by screening as most of the women had 
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not attended screening. When comparing stage at cancer diagnosis, ten year ovarian 
cancer free survival for stage I and II cancers was found to be simi lar for both MMR 
mutation carriers and BRCA mutation carriers (87% for both), however, ovarian cancer 
free survival for advanced stage ovarian cancers (stage III and IV) was found to be 53% 
for MMR mutation carriers and only 19% for BRCA carriers. When compared to the 
general population, 5 year ovarian cancer survival for advanced stage ovarian cancer was 
found to be 59% for MMR mutation carriers compared to 28% in the general population. 
They suggest that survival for advanced stage ovarian cancer may be better for MMR 
mutation carriers compared to BRCA carriers and the general population and that the 
MMR genes may predispose to a biologically different type of ovarian cancer that is 
characterized by early stage and more favorable prognosis. 
2.4 MOLECULAR BASIS OF LYNCH SYNDROME 
Lynch syndrome is due to a germ line mutation in one of several MMR genes. However, 
because searching for one of these MMR mutations is difficult and expensive, molecular 
prescreening can be perfo rmed. Microsatellite instability of the tumor, and loss of one or 
two of the MMR proteins in the tumor compared to normal tissue, are two tumor 
characteristics that can be used to identify CRC patients most likely to have LS. 
2.4.1 Microsatellite Instability 
Microsatellite instabili ty is a hallmark of LS and is detected in more than 90% of tumors 
in LS [Aaltonen 1993, 1994]. Microsatellites are short repetitive DNA sequences that 
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occur throughout the genome and MSI is caused by failure of the DNA MMR system to 
correct for errors in microsatellite repeat sequences that occur during DNA replication. 
International guidelines for the evaluation of MSI recommend using a set of fi ve 
microsatellite markers, namely, D2S 123, D5S346, D 17S250, BA T25 and BA T26 
[Boland 1998] and additionally BA T40 may be tested to increase the sensitivity of the 
test [Hendricks 2003]. Comparison of marker size in tumor tissue and unaffected tissue 
from the same individual is scored as MSI-high (MSI-H) if 30% or more of the tumor 
markers show instability, MSI-low (MSI-L) if less than 30% show instability, or 
microsatell ite stable (MSS) if none of the markers show instability. Because the majority 
of CRCs from patients wi th LS exhibit MSI, it can be helpful in diagnosing LS. However, 
MSI status alone cannot be used as a test for LS cancers because MSI is not specific to 
LS as it also occurs in up to 15% of sporadic CRCs [ Aaltonen 1994; Moslein 1996; 
Herman 1998; Lindor 2002]. Sporadic MSI-H CRCs are due to hypermethylation of the 
MLH1 promotor region, whereas, MSI-H tumors in LS are the result of a germ line gene 
mutation [Jasperson 20 1 0]. 
2. 4. 1. 1 Prediction of MSI in Colorectal Cancers 
As was stated previously, high frequency microsatellite instability is a feature of CRCs 
that arise in LS . However, testing of all tumors for microsatellite status in a population-
based setting would be a very non-specific and expensive way to identify LS cases. In 
2007, Jenkins et a l. [Jenkins 2007] identified pathology features (based on the tumor 
histology criteria included in the Revised Bethesda Guidelines, namely, the presence of 
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tumor infiltrating lymphocytes, a Crohn's-like lymphocytic reaction, mucinous or signet 
ring differentiation and a medullary or undifferentiated and solid growth pattern) and 
other clinical features (age at diagnosis and anatomic site of colon in the tumor) that 
independently predict MSI-H status. Identification of these features led to the 
development of the MsPath (Microsatellite instability by Pathology) model which uses 
easily assessable clinicopathologic characteristics to calculate a MsPath score. This 
simple scoring system can then be used to determine which tumors are to be selected for 
MSI or immunohistochemistry (IHC) testing and improves upon the sensi tivity and 
specificity of the Revised Bethesda Criteria. 
A more recent study by Hyde eta!. [Hyde 201 0], improved upon the existing MsPath 
model by analyzing and scoring additional histologic features (such as peritumoral 
lymphocytic reaction and increased proportion of plasma cells in the tumor stroma). 
From this analysis they developed the _eathological Rol_E in the Determination of 
Instability in Colorectal I umors (PREDICT) model. This model was superior in both 
sensitivity and specificity compared to the MsPath model. The authors conclude that 
histologic evaluation is superior to family history for identifying MSI-H CRCs and is an 
efficient and cost-effective method compared with collection of a detailed family history 
and confirmation of cancer diagnoses. Pathological evaluation is also more useful in 
situations where fami ly history data is limited and uninformative for identifying possible 
LS families. The PREDICT model can direct MSI testing to only those tumors likely to 
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be MSI-H, reducing the number of tumors to be tested. Prediction ofMSI-H tumors is an 
important first step in identifying CRC patients most likely to have LS. 
2.4.2 Immunohistochemistry 
Immunohistochemistry analysis uses specific antibodies to identify the presence or 
absence of MMR proteins (MLH 1, MSH2, MSH6 and PMS2) in tumor tissue. 
Immunohistochemistry is considered abnormal when one or more of the proteins is 
absent in the tumor tissue [Thibodeau 1996; Muller 200 1; de Jong 2004]. Since the MMR 
proteins form heterodimer complexes, distinct IHC patterns can be expected (Table 2.3). 
The MSH2 protein can form a heterodimer wi th either MSH6 or MSH3 , whereas MSH6 
can only pair with MSH2. Therefore, the specific IHC pattern observed in tumors of 
MSH2 carriers consists of absent staining of MSH2 and MSH6 and normal staining of 
MLH 1 and PMS2, whereas, if there is a germ line mutation in MSH6, MSH2 is normally 
stable because it can pair with MSH3 and the tumor will generally exhibit the absence of 
MSH6 only. Similarly, MLH1 can pair with PMS 1, PMS2 or MLH3, but PMS2 can only 
pair with MLH 1. Therefore, the IHC pattern for colorectal tumors from carriers of an 
MLH 1 mutation consists of absent staining for MLH 1 and PMS2 and normal staining for 
MSH2 and MSH6, whereas, the IHC pattern for tumors from PMS2 mutation carriers 
generally consists of only absent staining of the PMS2 protein [Vasen 2007a; Hampel 
2009]. These IHC patterns are a general rule of thumb for determining which MMR gene 
is causing LS but inconsistent findings are not uncommon [Woods 201 0]. 
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Immunohistochemistry is especially indicative of MMR mutations that result in 
truncation ofthe protein (such as nonsense, frameshift, splice site mutations and large 
genomic rearrangements) but is not always diagnostic in the case of missense mutations 
as the protein can be functionally abnormal but still be detected by IHC [Ramsoekh 2007; 
Hendricks 2006]. 
Table 2.3 IHC patterns associated with MMR mutations (Ramsoekh 2007] 
MMR Gene Mutation 
IHC Staining MLHJ MSH2 MSH6 PMS2 
MLHJ + + + 
MSH2 + + + 
MSH6 + + 
PMS2 + + 
MMR, mismatch repair; IHC, immunohistochemistry 
2.4.3 Performance of Molecular Prescreening 
Several studies have evaluated the results of MSI or IHC analysis in CRC tissue for the 
identification of MMR gene mutations. Palomaki et al. [Palomaki 2009] performed an 
evidence-based review of MSI and IHC as prescreening tests for the detection of MMR 
mutations and provided sensitivities and specificities for each test. They found that the 
sensitivity of MSI was 89% for patients with MLHJ and MSH2 mutations, and 77% for 
patients with MSH6 mutations. Sensitivities were lower if less than three mononucleotide 
repeats were included in the panel of microsatellites tested. Specificity of MSI testing 
was found to be 90%. The sensitivity of IHC was 83% regardless of the underlying MMR 
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gene involved, and specificity was 89%. This review, however, did not assess the 
sensitivity of MSI and IHC on the same tumor to screen for LS. 
Several prospective studies have evaluated the effectiveness of using both MSI and IHC 
on the same tumor for the detection of MMR mutations. One study to perform such an 
analysis was conducted by Pinol et al. [Pinol 2005] and evaluated over 1200 tumors. This 
population based study found that the sensitivity and specificity of MSI-H status was 
91% and 94%, respectively, for patients with MLHJ and MSH2 mutations. The sensitivity 
of IHC was lower at 82% but specificity was the same at 94%. In this study, MSI missed 
one MSH2 mutation (the tumor was MSS) and IHC missed one MLHJ mutation and one 
MSH2 mutation. Another study performed MSI and IHC for the four MMR proteins on 
500 tumors from unselected CRC patients [Hampel 2008]. They found sensitivities of 
I 00% and 94% and specificities of 90% and 88%, respectively, for MSI and IHC 
screening. A third study evaluated a population-based sample of unselected CRC patients 
diagnosed at age less than 45 years [Southey 2005]. In this higher risk group, MSI-H 
status was found to have a sensitivity of 72% and a specificity of 94% for patients with 
MLHJ, MSH2, MSH6 and PMS2 mutations. IHC analysis was found to have a sensitivity 
of 1 00% and a specificity of 94%. Of the five mutations missed by MSI analysis, four 
were MSH6 mutations with MSI-L status and one was a PMS2 mutation which was MSS. 
A combination ofMSI and IHC provides the most optimal selection for mutation 
analysis, however there is no consensus on whether MSI or IHC should be used as the 
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first step. MS I can indicate the presence of undiscovered pathogenic genes, whereas IH C 
can only detect loss of protein expression for already identified genes. Therefore, it has 
been suggested that IHC be used as the first step in fami lies with a high probability of 
carrying a mutation (e.g., families that fulfi ll the Amsterdam criteria) because the result 
can indicate which gene is mutated and direct mutational testing [Vasen 2007b] . MSI 
analysis can be performed first on famili es that fulfill the Bethesda criteria. In these 
cases, MSI can provide information on loss of MMR function for both the known MMR 
genes and for those yet to be identified. In those found to have MSI-H and MSI-L 
tumors, IHC can then be performed as a second step [Hendricks 2006; Vasen 2007a, 
2007b] . Other factors to be considered are time and cost. IHC is a faster, less expensive 
test than MSI and can direct mutational testing to the affected gene. Therefore, due to the 
fact that IHC has been shown to be almost equally effective as MSI [Pinol 2005; Hampel 
2008] some studies advocate IHC as the first step. 
Although the majority of tumors from patients with LS show high levels of MSI, 
restricting mutation analysis to MSI-H tumors only can miss a proportion of MSH6 and 
PMS2 mutation carriers. Several studies have shown that LS patients with an MSH6 
mutation had tumors that were MSI-L [Southey 2005 ; Barnetson 2006; Niessen 2006] 
and MSS [Barnetson 2006]. Simi larly, patients with a PMS2 mutation may have a lower 
rate ofMS I-H tumors than patients with MLHJ and MSH2 mutations [Southey 2005]. 
Also, in cases with a strong family history suggestive of LS but a MSS tumor, MSI 
analysis on a second tumor from the family should be performed to exclude the 
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possibility of a phenocopy [Vasen 2007a]. A phenocopy occurs when an individual 
shows the features characteristic of a particular genotype but is produced environmentally 
rather than genetically. 
Microsatellite instability and IHC is preferably performed on CRC tumor tissue, 
however, if this is not possible other tumor tissues can be analyzed (e.g. endometrial 
cancer). Unfortunately, the value of MSIIIHC in other LS-associated tumors is largely 
unknown. An American study looked at the feasibi li ty of molecular screening among 
unselected endometria l cancer patients and found that MSI status in these patients was 
less sensitive compared with MSI performed on CRC tumors [Hampel 2006]. Of the I 0 
deleterious germ line mutations identified ( 1 MLH 1, 3 MSH2 and 6 MSH6) , three MSH6 
mutations were missed by MSI analysis (2 were MSI-L and 1 was MSS) . Similar results 
were found in other studies and may be di rectly owing to the fact that a large proportion 
of endometrial carcinomas in MSH6 mutation carriers exhibit a MSI-L or MSS phenotype 
[de Leeuw 2000]. 
2.4.4 MLHl Promoter Methylation and BRAF Testing 
Sporadic MSI-H tumors are typically due to somatic hypermethylation of the MLHJ 
promoter region which leads to epigenetic silencing of the gene. Large population based 
studies have shown that a high proportion of MSI/hMLH 1 loss cases to be sporadic 
[Pino l 2005 ; Hampel 2008]. Therefore, in tumors with an MSI-H phenotype and absent 
staining of MLH 1, direct measurement of the methylation status of MLH 1 in the tumor 
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should be performed as well as genetic analysis of the BRAF gene. Mutations in the 
BRAF gene can cause disease in two ways. First, mutations can be inherited and cause 
birth defects. Second, mutations can appear later in life and cause cancers, such as CRC. 
BRAF mutations have been identified in approximately 70% of CRC tumors from 
individuals with MLHJ promoter methylation but have yet to be identified in patients 
with a MLHJ germline mutation [Palomaki 2009; Woods 2010]. Thus, performing 
additional BRAF testing and MLHJ promoter methylation analysis can differentiate 
between sporadic and LS-associated MSI-H tumors. 
2.5 DIAGNOSIS OF LYNCH SYNDROME 
Lynch syndrome is defined in terms of having a germline mutation in one of the DNA 
MMR genes. However, it is not feasible to test every CRC patient for one of these 
mutations [Lynch 2009a]. Diagnosis of LS is made even more difficult due to the fact 
that LS has a variable phenotype with respect to tumor site, age of onset and penetrance 
of disease. Identification of family members with an MMR gene mutation is very 
important for screening and management purposes as screening can be restricted to these 
individuals, whereas those without a mutation may be spared intensive surveillance 
[Ramsoekh 2007; Vas en 2007b]. There is no "gold standard" test for diagnosing LS but 
several strategies for identification of individuals with LS have been proposed. Family 
history based clinical criteria have been used to identify high risk families for further 
analysis, universal screening of all colorectal tumors has been proposed as a possible 
strategy for LS identification, algorithms have been designed for evaluation of patients 
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with suspected LS and models have been developed to predict the likelihood of carrying a 
germline mutation. 
2.5.1 Clinical Diagnostic Criteria 
Identification of fami lies at risk for LS should be based on clinical and family history 
criteria. Historically, the Amsterdam criteria were used in clinical practice to identify 
high risk families for further analysis. More than 50% of families with LS, however, fail 
to meet these criteria. As a result, the Amsterdam II and Bethesda guidelines were 
developed to try to identify a larger proportion of individuals at risk for LS. 
2. 5.1.1 Amsterdam I and II 
In 1990, the ICG-HNPCC established research criteria for the diagnosis of LS [Vasen 
1991]. These criteria, known as the Amsterdam criteria, included the following: 1) at 
least three relatives with CRC, one of them a first degree relative of the other two; 2) at 
least two successive generations affected; and 3) at least one CRC should be diagnosed 
before the age of 50. Also, all tumors should be verified by pathological examination and 
F AP should be excluded. These criteria were developed to standardize the diagnostic 
criteria for LS and to provide a basis for uniformity in collaborative studies. 
The initial Amsterdam criteria (Amsterdam criteria I) did not account for the extracolonic 
cancers found in LS and missed a number of at-risk individuals. For these reasons the 
Amsterdam criteria were revised in 1999 and included several extra colonic tumors. 
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These criteria, known as the Amsterdam criteria II , differed from the original criteria by 
including families with three relatives with an HNPCC-associated cancer (CRC, 
endometrial, small bowel , ureter or renal pelvis) as opposed to three relatives with CRC 
[Vasen 1999]. The Amsterdam criteria II were used in clinical practice to select 
individuals for mutation analysis of the MMR genes, however, these criteria were too 
stringent and many LS families were missed. In a large population-based review that 
performed MSI and DNA MMR gene testing on consecutive CRCs, only 42% of 
mutation carriers met the Amsterdam criteria II [Barnetson 2006]. Therefore, a fami ly 
which does not fulfill these criteria may still have a mutation in one of the MMR genes 
and should not be falsely reassured and excluded from genetic counseling, DNA testing 
or surveillance [Ramsoekh 2007]. 
2. 5. ! . 2 Bethesda Guidelines 
In 1996, the National Cancer Institute hosted an international workshop on HNPCC and 
proposed a set of guidelines that were later updated in 2004 [Rodriguez-Bigas 1997; 
Umar 2004]. The Bethesda guidelines were developed to select patients whose colorectal 
tumors should be tested for MSI. Tumors found to have microsatellite instability were 
subsequently tested for an MMR gene mutation. The revised Bethesda guidelines are 
listed in Table 2.4. 
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Table 2.4 The revised Bethesda guidelines for testing colorectal tumors for 
microsatellite instability (MSI) [Umar 2004] 
Tumors from individuals should be tested for MSI in the following situations: 
1. Colorectal cancer diagnosed in a patient who is less than 50 years of age. 
2. Presence of synchronous or metachronous colorectal or other HNPCC-associated 
tumorsa, regardless of age. 
3. Colorectal cancer with MSI-Hb histologl diagnosed in a patient who is less than 60 
years of aged. 
4. Colorectal cancer diagnosed in a patient with one or more first degree relatives with an 
HNPCC-related tumor, with one of the cancers being diagnosed under age 50 years. 
5. Colorectal cancer diagnosed in a patient with two or more first- or second-degree 
relatives with HNPCC-related tumors, regardless of age 
a Hereditary nonpolyposis colorectal cancer (HNPCC)-associated tumors include 
colorectal, endometrial, stomach, ovarian, pancreas, ureter or renal pelvis, biliary tract, 
and brain (usually glioblastoma as seen in Turcot syndrome) tumors, sebaceous gland 
adenomas and keratoacanthomas in Muir- Torre syndrome, and carcinoma ofthe small 
bowel 
b MSI-H = microsatellite instability-high in tumors refers to changes in two or more of 
the five National Cancer Institute-recommended panels of microsatellite markers 
c Presence of tumor infiltrating lymphocytes, Crohn's-like lymphocytic reaction, 
mucinous/signet-ring differentiation, or medullary growth pattern 
d There was no consensus among the Workshop participants on whether to include the 
age criteria in guideline 3 above; participants voted to keep less than 60 years of age in 
the guidelines 
Several studies have looked at whether the Amsterdam criteria II and revised Bethesda 
guidelines are adequate for identifying LS patients. To determine if these criteria are 
appropriate, studies have looked at the proportion of cases with an MMR gene mutation 
(mainly MLHJ and MSH2 mutations) that would be missed in a series of unselected 
patients with CRC. Vasen eta!. [Vasen 2007b] evaluated six studies [Aaltonen 1998 ; 
Debniak 2000; Salovaara 2000; Cunningham 200 I ; Hampel 2005a; Pinol 2005] and 
found that the sensitivity of the Amsterdam criteria II for detection of LS mutation 
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carriers was around 40%, while the sensitivity of the revised Bethesda guidelines was 
approximately 90%. The Bethesda guidelines have a high sensitivity, however, due to 
their less restrictive nature they have a low specificity; 80% or more of patients who meet 
the Bethesda guidelines will not have LS [Vasen 2007b]. 
2.5.2 Universal Testing Strategies 
Several factors, including small families , unrelated deaths, variable phenotype, and 
erroneous reporting have all limited the utility of the Amsterdam criteria and Bethesda 
guidelines in identifying LS families. Due to the fact that a substantial proportion of 
individuals with LS would be missed using these cl inical diagnostic criteria, studies have 
looked at performing MSI and/or IHC on all CRC patients to screen for MMR deficiency 
[Cunningham 200 1; Hampel 2005a, 2008; Julie 2008]. Similar work has also been done 
among endometrial cancer patients [Hampel 2006]. 
One of the first studies to examine the frequency of inherited CRC due to MMR 
defi ciency found that 5 1 of 257 (20%) unselected patients referred for CRC resection had 
evidence of defective MMR (MSI-H) [Cunningham 200 1]. Of the 51 patients with 
defective MMR, seven were found to have a germ line mutation, and of these seven 
individuals, only three had family histories that met the Amsterdam criteria. In one of the 
largest studies to evaluate a universal screening approach, 208 of 1066 (20%) patients 
were found to have MSI ( 135 MSI-H, 73 MSI-L), and 23 of these patients had a germline 
mutation causing LS [Hampel 2005a]. Among the 23 individuals found to have LS, only 
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three met the Amsterdam criteria, 18 met the Bethesda criteria and five did not meet 
either of these criteria. Similarly, a study evaluating 214 consecutive, newly diagnosed, 
CRC patients found that of the eight patients identified with a germ line mutation, only 
two of eight and six of eight met the Amsterdam II and revised Bethesda criteria, 
respectively [Julie 2008]. These studies show that 2 to 4% of unselected CRC cases are 
due to LS and that a substantial proportion of cases (more than 20%) would be missed 
using only the Amsterdam or Bethesda criteria. However, to find these extra cases would 
require a complex and expensive effort and more research is needed to determine the 
feasibility and cost effectiveness of these strategies. 
A recent study evaluating a comprehensive screening approach also compared the 
suitability of MSI or IHC as the primary screening method in detecting LS-associated 
CRC [Hampel 2008]. Among the 500 CRC patients studied, 18 were found to have a 
germline mutation. All 18 patients with LS had MSI-H tumors and 17 of 18 patients with 
LS were correctly predicted by IHC analysis. This study showed that MSI and IHC were 
quite similar in having high sensitivity to detect LS in population-based studies. In large-
scale screening studies, performing IHC instead of MSI as the primary screening method, 
will lead to considerable savings in time, effort and cost. 
Due to the high risk of endometrial cancer among LS patients, work has also been done 
to determine the freq uency of LS among endometrial cancer patients. One such study 
evaluated the feas ibility of molecular screening among 543 unselected endometrial 
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cancer patients [Hampel 2006]. All tumors underwent MSI testing and 118 patients were 
found to have MSI-positive tumors (98 MSI-H, 20 MSI-L) . Of those with a MSI-positive 
tumor, nine were found to have a deleterious germline mutation. One additional patient 
with a MSI-negative tumor was also found to have a mutation. Of the 10 LS patients 
identified, three met the Amsterdam II criteria, two met the revised Bethesda criteria, and 
seven did not meet either of these criteria. This study shows that approximately 2% of 
unselected endometrial cancer cases are due to LS and that 70% of cases would be 
missed using only clinical diagnostic criteria. 
2.5.3 Mutation Prediction Models 
Due to the limitations of the Amsterdam and Bethesda criteria in predicting patients with 
LS, strategies involving universal testing of all CRC tumors for MSI and/or IHC were 
undertaken. These studies demonstrated that a substantial proportion of LS patients 
would be missed if only clinical diagnostic criteria were used but that it would require a 
complex and expensive effort to find additional patients using a comprehensive 
molecular screening approach . Even if universal MSIIIHC screening of all CRC tumors 
was feasible, it may still fail to identify cases in which MMR mutations disrupt MMR 
function but do not result in MSI or when IHC results are found to be normal despite a 
nonfunctional MMR protein. 
In recent years predictive models have been developed in an attempt to improve upon the 
Amsterdam and Bethesda criteria and to reduce the burden of population-based molecular 
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screening in detecting patients with LS. These models utilize personal and family history 
to predict the likelihood that an individual carriers an MMR gene mutation. A major 
advantage of prediction models is that these models provide a quantitative estimation of 
the likelihood of an individual carrying a mutation instead of a bivariate (yes/no) 
assessment as given by clinical diagnostic criteria. Models vary widely with respect to the 
MMR genes they predict, the patient populations used to develop and validate the model, 
the clinical variables used to predict risk and in the statistical methodology used . 
Wijnen et al. [Wijnen 1998] were the first to develop a multivariable model for prediction 
of MLH 1 and MSH2 mutations. They identified mean age at diagnosis of CRC within a 
family, fulfillment of the Amsterdam criteria, and presence or absence of endometrial 
cancer in the family, as significant predictors of the presence of MLHJ and MSH2 
mutations. More recently, the MMRpredict [Barnetson 2006], PREMM 1,2 [Balmana 
2006] and MMRpro [Chen 2006] models have been developed and validated. The 
MMRpredict and MMRpro models estimate the probability of carrying a deleterious 
mutation in MMR genes MLHJ , MSH2, and MSH6, whereas the PREMM u model was 
originally developed to predict mutations in MLHJ and MSH2 genes. The PREMM 1.2 has 
recently been expanded to include MSH6 mutations (PREMM 1,2,6) [Kastrinos 20 11]. 
2.5.3. 1 Validation of Models 
The performance of the above mentioned prediction models in clinical practice and their 
ability to predict mutation carrier status in cohorts with varying risks of CRC have 
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recently been published [Balmana 2008 ; Green 2009; Pouchet 2009; Monzon 201 0]. Two 
studies have looked at mutation prediction models in low risk settings and found varying 
results. Balmana eta!. [Balmana 2008] evaluated the PREMM 1,2 and MMRpredict 
models in a large, low-risk, population-based cohort of over 1200 newly diagnosed CRC 
cases and were unable to demonstrate that either of these models were superior to each 
other or the revised Bethesda guidelines at predicting an MMR mutation. This study, 
however, included only eight mutation carriers and no statistical comparisons were made. 
Another study compared the diagnostic utility of four models (Leiden, MMRpredict, 
PREMM 1.2 and MMRpro) in a population based cohort of over 700 consecutive patients 
with CRC [Green 2009]. After correcting for family size, Green et a!. found that the 
MMRpredict model was better at predicting patients who were at high risk of carrying an 
MMR mutation. 
Pouchet et a!. [Pouchet 2009] and Monzon et a!. [Monzon 20 I OJ looked at the 
performance of these models in predicting a LS-causing mutation in individuals with a 
family history of CRC. Pouchet eta!. evaluated three models (MMRpredict, PREMM1,2 
and MMRpro) and found that all three carried out well in a cancer genetics setting, with 
PREMM 1.2 having slightly better predictive abilities. Monzon eta!. evaluated these three 
models along with the Wijnen and Myriad Genetics models [Myriad Genetics 
Laboratory] and found similar results, with the PREMM 1,2 model having the best 
predictive performance. More studies should be performed to corroborate these findings 
in both low-risk and moderate- to- high risk CRC populations. 
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2.5.4 Mutation Analysis 
Due to the heterogeneity of the mutation spectrum in MMR genes, germ line mutation 
testing in LS is very expensive and time consuming and is normally only recommended 
when high risk individuals have been identified. Therefore, mutation analysis is normally 
performed after MSI and/or IHC have been shown to be indicative of a germline mutation 
or if there is a very high suspicion of a mutation due to fami ly history [Ramsoekh 2007]. 
When MSI and IHC analysis do not indicate abnormalities, germline mutation testing is 
not useful . 
The presence of a deleterious germ line mutation in one of the MMR genes confirms the 
suspected clinical diagnosis of LS. Germline mutations resulting in LS have been found 
in 4 MMR genes : MSH2 [Fishel 1993], MLHJ [Bronner 1994] , PMS2 [Nicolaides 1994] 
and MSH6 [Akiyama 1997; Miyaki 1997]. Both point mutations and large genomic 
deletions have been identified and, as such, gene testing should include both full 
sequencing of the gene and large rearrangement testing. Large deletions account for 
approximately 26% of MSH2 mutations, 22% of MLHJ and PMS2 mutations and 7% of 
MSH6 mutations [Hampel 2009]. 
Mutation analysis is performed in DNA from blood derived lymphocytes and should be 
performed on the youngest family member with CRC. Gene testing can be carried out 
using a variety oftechniques: denaturating gradient gel electrophoresis (DOGE), 
multiplex ligand dependent probe amplification (MLPA) for the detection of large 
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genomic deletions, and direct sequencing. Once a germline mutation is identified in an 
affected individual, presymptomatic diagnostic testing can be offered to healthy family 
members. This type of testing has lower cost and higher accuracy than the initial gene 
testing needed to identify the specific mutation [Lynch 2009b). A mutation in any of the 
four MMR genes is diagnostic for LS, however, sometimes the result of genetic testing is 
less clear. Genetic variants of uncertain significance are detected fairly frequently ( ~ 7%) 
in the MMR genes and can make interpretation of the genetic test results difficult 
[Hampel 2009). To determine whether the mutation is likely to be deleterious or if the 
variant is tracking with cancer in the fami ly, genetic testing for these variants can be 
carried out in other affected family members, but even these results may be inconclusive. 
Until the genetic variant has been determined to cause LS, predictive testing should not 
be offered to at-risk relatives. 
2.5.5 Familial Colorectal Cancer Type X (FCCTX) 
Almost half the fami lies meeting the Amsterdam-! criteria do not have LS by the current 
definition ; they do not have MSI or show abnormal staining for the MMR proteins. 
Clustering of CRC by chance or yet-to-be defined genetic defects may be responsible for 
the disease pattern seen in these families . The term ' familial colorectal cancer type X 
(FCCTX)' has been used to describe families that fulfill the Amsterdam-! criteria but 
who have no evidence of deficient MMR [Lindor 2009). Lindor et al. [Lindor 2005] 
compared cancer risks in Amsterdam I families with an MMR mutation to Amsterdam I 
families without a MMR mutation. Families in the latter group did not share the same 
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cancer incidence as LS families (i.e. , MMR deficiency) : CRC risks were lower and risks 
for other LS-associated cancers did not appear to be increased. Other studies have shown 
a later age of onset for CRC and a greater proportion of left-sided tumors versus right-
sided tumors for FCCTX families compared to LS families [Lior 2005 ; Mueller-Koch 
2005; Valle 2007; Woods 20 10]. Slower progression from adenoma to carcinoma and 
fewer synchronous, metachronous and extracolonic cancers have also been reported. 
These differences in the clinical features and the differences in the molecular features of 
the FCCTX tumors [Abdel-Rahman 2005] distinguish this group from those with LS and 
from those with sporadic CRC. 
2.6 GENETIC TESTING & SCREENING IN LYNCH SYNDROME 
The key to managing and preventing cancer development in LS is early diagnosis through 
a comprehensive family history, followed by germl ine mutation testing if appropriate, 
and targeted screening and management for patients with mutations [Lynch 2009b]. 
2.6.1 Genetic Testing and Counseling 
There are multiple benefits to genetic testing in LS, including a more accurate diagnosis, 
determination of risk for other family members and targeted screening and surveillance 
options for positive gene carriers. However, genetic testing often provides a diagnosis 
long before any symptoms are experienced and this can have considerable psychosocial 
and management consequences. It is therefore recommended that individuals receive 
appropriate counseling and provide informed consent before genetic testing. The 
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informed consent document should contain a general description of the test, including the 
benefits, risks and limitations of testing, and the meaning of positive, negative and 
uninformative results. 
The protocol for genetic testing of the American Society of Clinical Oncology 
recommends that three sessions be performed [ASCO 2003]. During the first session, 
issues relating to the reasons for testing, the clinical features of the hereditary CRC 
syndrome, the mode of inheritance, the consequences of the test results, the options for 
treatment in case of a positive test result, and the DNA testing procedure itself are 
discussed. In the second session blood samples are taken and in the third session the test 
results are disclosed. The third session also involves reviewing preventative surveillance 
and surgical recommendations, exploring the psychosocial impact of the result, and 
discussing the importance of disclosure to family members and the impact the results 
may have on them [Aronson 2009]. 
As was stated earlier, once a mutation has been detected in an affected individual, healthy 
family members can undergo mutation-specific testing. One of the strongest motivators 
for presymptomatic testing is the relief from uncertainty. Other motivators include the 
desire to define the risk to their children and the need to determine appropriate 
surveillance and management options for themselves. Deterrents to genetic testing 
include concerns about loss of health insurance, impact on the family and the psychologic 
impact of a positive test result [Aronson 2009]. A positive test result may lead to 
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emotional distress regarding personal cancer risk and the need for frequent surveillance 
or prophylactic surgery. A negative test may result in emotional relief and avoidance of 
unnecessary surveillance but may also lead to feelings of guilt towards affected relatives 
[Ramsoekh 2007]. Genetic testing has both benefits and disadvantages, but it is necessary 
for providing targeted screening and management programs for at-risk family members. 
2.6.2 Screening in Lynch Syndrome 
Screening and management programs for LS are based on knowledge of the natural 
history of disease and the cardinal features of LS. Cancer-related morbidity and mortality 
may be significantly reduced through highly targeted screening programs that take into 
account the types of cancers involved, the age at onset of these cancers and the ri sk of 
developing these cancers for affected individuals. Presently, screening for CRC in LS 
requires complete colonoscopy to the cecum every 1 to 2 years starting at ages 20 to 25 
years, or 10 years younger than the youngest age of the person diagnosed in the fami ly. 
However, due to the attenuated phenotype (later age at CRC onset and lower penetrance) 
seen in families with an MSH6 or PMS2 mutation, the recommendation is to start at age 
30 years [Lindor 2006; Lynch 2008a; Senter 2008]. Gynecologic screening requires 
endometrial biopsy, transvaginal ultrasound, and CA 125 testing, every 1 to 2 years 
staring at ages 30-35 years [Lindor 2006; Lynch 2008a; Schmeler 2008; Meyer 2009]. 
Other screening procedures include endoscopy for families with a hi story of gastric 
cancer and urine cytology and ultrasound for evaluation of the ureter and renal pelvis. 
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Furthermore, education and genetic counselling regarding LS should be initiated at age 
21 years [Lindor 2006; Lynch 2008a]. 
2. 6. 2. 1 Colon Screening 
Although LS accounts for only a small percentage of the total CRC burden, the high risk 
of cancer among affected family members makes screening an important clinical 
endeavor [Johnson 2006]. Detection and treatment of CRC at an early stage can save 
lives, however, prevention of CRC by colonoscopic screening may have a far greater 
impact on morbidity, mortal ity and the economic burden to the healthcare system [Helm 
2003; Green 2009; Kopciuk 2009]. 
Determining the impact of screening in LS is difficult because ethically it is not possible 
to randomly allocate mutation carriers to "no screening". As such, there are no 
randomized, controlled, clinical trials looking at the effectiveness of screening in LS 
[Johnson 2006; Stupart 2009]. Several observational studies on the efficacy of regular 
colonoscopic screening have been reported [de Vos tot Nederveen Cappel 2002; Dove-
Edwin 2005, 2006; de Jong 2006b; Mecklin 2007; Engel 2010; Vasen 2010]. 
Currently, two cohort studies provide the best available evidence in support of 
colonoscopic screening in LS [Jarvinen 2000; Stupart 2009]. A prospective cohort study 
by Jarvinen et a!. [Jarvinen 2000) evaluated the efficacy of screening in a prospective 
cohort study over 15 years. This study involved a heterogeneous group of patients and 
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included patients with mutations of several mismatch repair genes and also patients with 
no known mutation but who met the clinical criteria for LS . This study demonstrated a 
significant difference in the rate of CRC and death between those who were screened 
every 3 years and those who did not receive screening. Colonoscopic screening was 
found to decrease the CRC rate by 62%, prevent CRC deaths, and to decrease overall 
mortality by about 65% in LS families. A more recent prospective cohort study by 
Stupart et al. [Stupart 2009] investigated whether screening colonoscopy improves 
survival in subjects who carry a single MLHJ germline mutation. This study showed that 
screening colonoscopy was associated with improved overall and CRC-related survival 
and that the median age at onset of CRC was delayed by more than 20 years in the 
screened group. 
The previous two studies both provide evidence of the benefit of colonoscopic screening 
in LS but neither adjusted for survivor bias nor evaluated screening based on gender. 
Survivor bias is inherent in screening studies as only those who are alive and disease-free 
can enter primary screening programs leading to an overestimation of the impact of 
screening. Due to the phenotypic di fference in age at onset and lifetime risk of CRC 
between male and female mutation carriers [Green 2002; Stuckless 2007; Kopciuk 2009] , 
and the potential differences in enrollment and compliance between males and females, 
screening effectiveness may differ by gender. 
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Screening may never completely prevent CRC from developing, but it may be possible to 
further improve the reduction in the number of CRCs diagnosed by reducing the 
screening interval to one year. Previously, Lynch et al. [Lynch 2008a] , argued for a 
shorter screening interval due to the relatively high incidence of CRC in screened 
subjects with LS. Given the high incidence of CRC and the accelerated adenoma-
carcinoma sequence in LS [de Jong 2004b ], annual screening colonoscopies may be 
appropriate for this group. In 2006, de Jong et al. [de Jong 2006] studied colonoscopic 
screening in 215 mutation carriers aged 40-60 years. Of the 34 screen-detected CRCs 
identified, 13 were diagnosed within two years of a previously normal screening 
colonoscopy. More recently, a study by Vasen et al. [Vasen 2010] evaluated the 
effectiveness of a one-to-two year screening interval in reducing the ri sk of CRC in LS. 
Thirty-three of 745 ( 4.4%) mutation carriers developed CRC under survei llance . Of these 
33 , 14 developed their cancer within the 1-2 year recommended screening interval and an 
additional two developed it within one year. Another recent prospective cohort study by 
Engel et al. [Engel 20 I 0] evaluated the efficacy of annual colonoscopies in detecting 
adenomas and CRCs. This study found that 19 of 43 interval cancers detected by 
screening were preceded by a normal colonoscopic exam within the recommended 
interval of 12 months. In the absence of a prospective controlled trial to determine the 
optimal screening interval, these studies provide evidence for reducing the screening 
interval. 
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Improvement in the technique of colonoscopy examinations may also reduce CRC 
development. As was stated earlier, Engel eta!. [Engel 201 OJ found that 19 individuals 
developed CRC within 1 year of their previous colonoscopy. These tumors were likely to 
have been missed lesions resulting from poor quality colonoscopic examinations. Studies 
have shown that more than 50% of adenomas in LS are missed by conventional 
colonoscopy and that many ofthese missed lesions are small, flat adenomas [Hurlestone 
2005; Lecomte 2005; East 2008; Stoffel 2008]. Given the accelerated adenoma to 
carcinoma sequence in LS, improved detection of these small lesions may be very 
important in preventing CRC tumors from developing. 
Hurlstone eta!. [Hurlestone 2005] and Lecomte eta!. [Lecomte 2005] compared back-to-
back examinations in which standard colonoscopy was followed by chromoendoscopy, 
performed by spraying dye (indigo carmine solution) on the colorectal mucosa during 
colonoscopy, and found that chromoendoscopy more than doubled the number of 
adenomas detected in individuals with LS. East et a!. [East 2008) found that using narrow 
band imaging (a novel endoscopic technology that highlights superficial capillaries in the 
mucosa and improves contrast for adenomas) as the second exam nearly doubled the 
number of adenomas detected in LS patients. Stoffel et a!. [Stoffel 2008) compared 
chromoendoscopy versus standard colonoscopy with intensive inspection (lasting > 20 
minutes) for detecting polyps missed by conventional colonoscopy. They found that the 
second examinations more than doubled the number of adenomas detected but that there 
was no significant difference between the use of chromoendoscopy and intensive 
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inspection in detection of additional adenomas. More recently, a study by Ramsoekh et 
al. [Ramsoekh 201 0] found that the use of autofluorescence endoscopy, a technique 
specifically designed to probe large areas of mucosa using short wavelength light 
(typically blue light) to detect neoplasias, resulted in a 34% increase in the adenoma 
detection rate. Prevention of CRC in this high risk group is important and further 
evaluation is needed to determine the most effective colonoscopic imaging technique for 
detecting adenomas. 
2. 6. 2. 2 Gynecological Screening 
Endometrial cancer is the most common extracolonic tumor associated with LS and in 
some mutation carriers the risk of developing endometrial cancer exceeds the risk of 
CRC development [Dunlop 1997; Aarnio 1999; Hendricks 2004; Hampel 2005 ; Stuckless 
2007]. Female mutation carriers are also at an increased risk of developing ovarian 
cancer. Various studies have shown colonoscopic screening in LS mutation carriers to 
reduce the risk of CRC development and improve survival [Jarvinen 2000; de Jong 
2006b; Stupart 2009]. However, unlike CRC, the efficacy of screening for gynecological 
cancers in LS remains controversial. 
The survival rate of LS-associated endometrial cancer has previously been proven to be 
favorable with an overall 5-year cumulative survival rate of 88% [Boks 2002]. Given the 
early stage at presentation and the good prognosis of endometrial cancer, it is unknown 
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whether screening for this cancer is necessary at all or if it would improve morbidity or 
mortality in female LS carriers. 
Annual or biennial screening for endometrial cancer using TVU (or in some cases 
transabdominal ultrasound) was evaluated in 269 women from families suspected of 
having LS [Dove-Edwin 2002]. During a 13 year observation period, the study detected 
no premalignant lesions or endometrial cancers, but two interval cancers were detected 
approximately 5 months and almost 2 years after a normal ultrasound. Both tumors were 
diagnosed at an early stage (FIGO stage I). FIGO staging is a tumor staging system 
established and revised by the International Federation of Gynecology and Obstetrics 
(FIGO) that takes into account the postoperative surgical pathology of the specimen. A 
study of 41 women from LS fami lies, who underwent screening by transvaginal 
ultrasound fo llowed by aspiration biopsy in suspected cases, found three malignant 
lesions (with complex atypical hyperplasia) after a median foll ow-up of 5 years [Rijcken 
2003]. No endometrial cancers were detected by screening but one interval cancer was 
diagnosed as a result of clinical symptoms 8 months after a normal transvaginal 
ultrasound. This tumor was diagnosed at an early stage (FIGO stage IB). Another study 
reported the results of screening by TVU combined with aspiration biopsy for the 
detection of endometrial cancer [Renkonen-Sinisalo 2006] . This study evaluated 175 LS 
mutation carriers and found 11 screen detected cancers and 14 premalignant lesions 
which may become cancerous. Two interval cancers were also diagnosed 3 and 31 
months after a previous screening visit. One additional endometrial cancer was found 
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during prophylactic hysterectomy that was performed in addition to a colectomy for 
cancer. Out of the II screen-detected cancers, six would have been missed without 
routine endometrial sampling. Women in the screened group were also compared to 83 
mutation carriers with endometrial cancer who did not undergo screening. The stage 
distribution and mortality tended to be more favorable in the I4 endometrial cancer cases 
in the screened group (no deaths) compared to the 83 symptomatic mutation carriers (7 
deaths). This diffe rence in survival curves ( I 00% vs. 92% at I Oyears), however, was not 
statistically significant. 
More recently, a study of I 00 women belonging to suspected Lynch syndrome fami lies 
found three atypical hyperplasias and one endometrial cancer in 64 visits where routine 
endometrial samplings were perfo rmed [Gerritzen 2009]. One case of atypical 
hyperplasia and two endometrial cancers were also detected in 28 samples performed 
because of abnormal screening results in 22 1 visits. These studies suggest that 
endometrial cancer screening with routine endometrial biopsy is more efficient in 
diagnosing endometrial (pre)malignancies than TVU alone. They provide guidance on 
how to perform screening but they do not ful fi ll the criteria for making evidence-based 
decisions. Although screening for endometrial cancer is controversial due to early stage 
at diagnosis and good prognosis, there may be benefit if the cancers can be detected at an 
even earlier stage when hysterectomy alone is effective. Broaddus et a!. [Broaddus 2006] 
found that 22% of their LS-associated endometrial cancers were stage II or III and would 
require additional adjuvant radiation therapy or chemotherapy. Detection of very early 
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stage cancers can therefore provide the opportunity to avoid extensive adjuvant 
therapy/treatment. 
A recent population-based randomized controlled trial found that annual screening of 
women with CA I25 testing and TVU compared to usual care did not reduce mortality 
from ovarian cancer (mortality RR= I.18; 95% CI 0.82-1.20 [Buys 20 II]. Annual 
screening of women at increased fami lial risk of ovarian cancer, using ultrasound and 
CA-1 25 measurements, has not led to early stage detection or improved survival [Evans 
2009]. Few studies have looked at the usefulness of these tests for ovarian cancer 
screening in LS famil ies only. Rijcken et al. [Rijcken 2003] found no abnormal ities on 
TVU nor did they find any elevated CA-125 values. No ovarian cancers were diagnosed 
through screening nor were any interval cancers detected. Another study by Renkonen-
Sinisalo eta!. [Renkonen-Sinisalo 2006] found four endometroid-type ovarian cancers, 
however, none were detected by screening. Two cancers were diagnosed by symptoms 2 
and 5 months after normal survei llance visits (stages III and I), and two were detected 
incidentally during an operation performed for endometrial cancer or complex 
hyperplasia (both stage I). A third study detected one ovarian cancer through screening, 
however, thi s cancer was a FIGO stage IIIC cancer [Gerritzen 2009] . Of the fi ve ovarian 
cancers diagnosed in these three studies, only one was detected through screening and it 
was found at an advanced stage suggesting no benefit of ovarian cancer screening in thi s 
population. 
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2. 6. 2. 3 Screening.for Extracolonic Cancers 
Other cancers associated with LS include cancer of the stomach, ureter, renal pelvis, 
small bowel , bile ducts and tumors of the brain. However, the incidence of many of these 
cancers is too small to warrant routine screening [Watson 2008]. Experts have suggested 
that if a family shows a clustering of gastric cancer, surveillance by means of endoscopy 
examination can be considered, or if a clustering of urothelial cancers is seen, screening 
for these cancers staring at age 30 to 35 years using annual urine analysis with cytology 
and renal ultrasounds can be performed. However, screening by these methods is 
unproven and no data exist on the effectiveness of these approaches [Vasen 2007a; 
Grover 20 I 0]. 
2.6.3 Screening in Families Without an Identified Mutation 
2. 6. 3.1 FCCTX 
As was stated earlier, FCCTX families are characterized by a more advanced age of onset 
of CRC and by absence of endometrial cancer or other extracolonic tumors when 
compared to LS families . Lindor et a!. [Lindor 2005] reported that the risk of developing 
CRC in these families was only increased by a factor of 2.3 and no increased risk was 
seen for other cancers. They suggest that these FCCTX families are comprised of (1 ) 
some cancer aggregation occurring by chance alone, (2) some aggregation related to 
shared lifestyle factors , and (3) some yet to be defined genetic syndromes. They propose 
that these families should be managed based on a customized assessment of the pedigree 
and not automatically screened based on the screening algorithms for LS families. 
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Another study compared the results of colonoscopic surveillance in families with 
clustering of CRC with and without MSI [Dove-Edwin 2006]. They found that both 
groups were at an equal risk of developing high-risk adenomas but that CRC was only 
identified in families with MSI tumors. They propose that FCCTX families require 
colonoscopic surveillance but that the interval could be lengthened because the risk of 
(interval) cancer is low. Based on these studies, Vasen eta!. [Vasen 2007b] have 
suggested the following cancer screening recommendations for FCCTX families: (1 ) 
colonoscopy at 3-5 year intervals, starting 5-l 0 years before the first diagnosis of CRC or 
at > 45years, and (2) screening for cancer of the endometrium is not indicated. In families 
that meet Amsterdam criteria I, but in whom tumor MSI testing or genetic testing is not 
feasible, screening recommendations should be the same as those proposed for LS 
families. 
2. 6. 3. 2 Novel Genes 
Given that a large proportion of high-risk families have no detectable mutations in the 
most commonly mutated MMR genes, it is possible that other colorectal cancer 
predisposition genes could be responsible for disease in these families [Woods 2005; 
Woods 201 0]. It is also possible that current mutation detection methods are inadequate 
to detect large deletions or rearrangements. Families which are highly suspicious for LS 
but in whom no known mutation was found should follow the same screening 
recommendations as those proposed for families with a known MMR mutation. 
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2.7 SURGICAL MANAGEMENT OF LYNCH SYNDROME 
2.7.1 Treatment for CRC 
Lynch syndrome patients have an increased risk of developing multiple (synchronous and 
metachronous) CRCs and this has an impact on surveillance and management options for 
these individuals. The options for surgical management of a colon cancer in LS patients 
include either a standard segmental colectomy or a subtotal (total) colectomy with 
ileorectal anastomosis. 
Several studies have looked at whether a subtotal colectomy instead of a segmental 
resection might be the preferred treatment in LS patients. A Finnish study reported that 
over a 7 year period, metachronous CRCs developed in 41 % ( 15/3 7) of HNPCC patients 
who underwent a segmental resection compared to 24% ( 411 7) of patients who underwent 
a subtotal colectomy [Mecklin 1993]. In a Dutch study of proven mutation carriers, the 
I 0-year cumulative risk of developing CRC was found to be 16% after partial colectomy 
and 3.4% after subtotal colectomy [de Vos tot Nederveen Cappel 2002]. More recently, a 
retrospective study examined patients who had undergone segmental colectomy 
compared to patients who had a total or subtotal colectomy with ileorectal or ileosigmoid 
anastomosis [Kalady 20 1 0] . After a median fo llow-up of almost 7 years, high risk 
adenomas were detected in 22% of patients who underwent segmental colectomy 
compared to 11 % in the total/subtotal colectomy group. Similarly, 25% of patients in the 
segmental colectomy group developed a metachronous CRC versus 8% in the 
total/subtotal colectomy group. 
49 
In a study by de Vos tot Nederveen Cappel et al. [de Vos tot Nederveen Cappel 2003], a 
decision analysis (Markov model) was performed to compare the life expectancy of 
patients undergoing a subtotal colectomy or a segmental colon resection. The results 
indicated that a subtotal colectomy performed at a young age(< 47 years) would lead to 
an increased life expectancy of up to 2.3 years. However, a subtotal colectomy in a 67 
year old would lead to an increased life expectancy of up to 0.3 years. A study by 
Natarajan et al. [Natarajan 2010] found that time to second CRC was shorter for those 
who underwent limited resection (controls) at initial CRC diagnosis compared to those 
who underwent a subtotal colectomy( cases). Time to second CRC ranged from 16 to 1 7 5 
months for the cases and 6 to 160 months for the controls. In view of these findings and 
the substantial risk of developing a metachronous tumor, it has been suggested that 
subtotal colectomy with ileorectal anastomosis be the preferred treatment in young 
patients presenting with CRC, while segmental resection might be appropriate in older 
patients [Ramsoekh 2007; Vasen 2007b]. Whether patients undergo a subtotal colectomy 
or a segmental resection, the residual colon and rectum must be evaluated yearly. 
Ultimately, patient preference and issues related to compliance with follow-up 
surveillance will be major determinants in this decision. 
There is limited data regarding the possible benefit of prophylactic colo rectal surgery in 
patients with LS. Natarajan et al. [Natarajan 201 0] found that none of the 8 patients who 
underwent prophylactic colectomy developed CRC during the study period. In a previous 
study, a decision analysis model was used to compare the efficacy of surveillance and 
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prophylactic colectomy in LS mutation carriers [Syngal 1998]. Compared to no 
intervention, surveillance led to an increased life expectancy of 13.5 years and 
prophylactic proctocolectomy led to an increased life expectancy of 15.6 years. The 
benefits of colectomy compared to surveillance decreased with increasing age and when 
health related quality of life was considered, surveillance led to the greatest quality 
adjusted life expectancy benefit. Prophylactic colectomy is not generally recommended 
due to decreased quality of life, but could be considered for patients who are unwilling to 
undergo regular colonoscopic screening. 
2.7.2 Prophylactic Surgery for Gynecological Cancers 
Lynch syndrome patients are at a high risk of developing endometrial cancer and a 
moderately increased risk of developing ovarian cancer, and as such, women with LS 
must decide between continued gynecological screening or prophylactic surgery. During 
the past several decades more effective and acceptable methods for CRC screening have 
become available, however, this is not the case for gynecological screening. The methods 
for endometrial screening are limited and ovarian screening techniques remain 
unsatisfactory. The diagnosis of interval endometrial and ovarian cancer is not 
uncommon and false-negative test results occur [Lynch 2007]. While data regarding the 
efficacy of gynecological screening is lacking, there is evidence of efficac y for 
prophylactic surgery [Lindor 2006; Vasen 2007b] . 
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Schmeler eta!. [Schmeler 2006] conducted a retrospective study to determine whether 
the risk of gynecologic cancers among women with LS was reduced after prophylactic 
surgery. Sixty-one mutation carriers who had previously undergone hysterectomy alone 
or with bilatera l salpingo-oophorectomy (BSO) were matched with 2 1 0 mutation carriers 
who had not undergone hysterectomy. No endometrial cancers developed in the women 
who underwent hysterectomy compared with 69 endometrial cancers (33%) in the 
controls, however, three endometrial cancers were incidentally diagnosed at the time of 
prophylactic hysterectomy, two tumors were at stage I and one was at stage II. In 
addition, 47 mutation carriers who had undergone previous hysterectomy with BSO were 
matched with 223 carriers who had not undergone surgery. None of the women who had 
undergone surgery developed ovarian cancer, however, 12 (5%) of the controls 
developed ovarian cancer. This study showed a decrease in the incidence of 
gyneco logica l cancers but did not address the effects of prophylactic surgery on survival 
and on deaths due to gynecological cancers. Further prospective studies with longer 
follow-up are needed to confirm the role of prophylactic surgery in preventing 
endometrial and ovarian cancer and in assessing the differences in survival between those 
who undergo prophylactic surgery and those who do not. 
The disadvantages of prophylactic hysterectomy and BSO include surgical compl ications 
(most commonly, bleeding, infection, and injuries to the urinary tract and bowel) and 
premature menopause. In the study by Schmeler et a!. [Schmeler 2006], surgical 
complications occurred in one of the 6 1 ( 1.6%) women who underwent prophylactic 
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surgery. This is consistent with complications rates of I% - 9% reported in other studies 
[Goodno 1995 ; Kovac 2000). 
Despite screening, occult cancers can be found at the time of prophylactic surgery 
[Schmeler 2006; Pistorius 2006]. At the time of surgery, the uterus and ovaries should be 
carefully assessed. The pathologist should be advised of the high ri sk of gynecological 
cancers and the specimens carefully examined intraoperatively, with frozen sections 
obtained if necessary. In addition, the surgeon should be prepared to complete staging 
operation in the case of occult carcinoma [Schmeler 2006]. 
Given the demonstrated benefit of prophylactic surgery and the lack of data on the 
effi cacy of screening for gynecological cancers, risk-reducing surgery is the 
recommended option for women who have completed childbearing [Manchanda 2009] . 
Data derived from Markov modeling confi rms that annual screening followed by 
prophylactic surgery at age 40 years as the most effective gynecologic cancer prevention 
strategy [K won 2008]. Other studies evaluating the cost-effectiveness of management 
strategies for women with LS using decision analytic models also support risk reducing 
surgery rather than annual gynecologic screening or annual gynecologic examinations 
[Chen 2007; Yang 20 11]. In addition, women with LS are at an increased risk of 
synchronous and metachronous cancers, specifically, CRC and endometrial cancer or 
ovarian cancer [Lu 2005 ; Schmeler 2006]. It has therefore been suggested that women 
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who undergo surgery for CRC be offered concurrent prophylactic hysterectomy with 
BSO [Lindor 2006]. 
2.7.3 Chemotherapy 
Chemotherapeutic regimes for CRC currently include 5FU with or without leucovorin, 
oxaliplatin and irinotecan [Ramsoekh 2007; Vasen 2007b]. These fluorouracil based 
agents have proven effective for the treatment of CRC and are considered the gold 
standard in adjuvant chemotherapy for bowel cancer [Vasen 2007a]. However, the 
effectiveness ofthese agents in LS are unknown. A few studies have reported on the 
efficacy of 5FU in MSI-H tumors but the results have been contradictory [Liang 2002; 
Fallik 2003 ; Ribic 2003 ; Carethers 2004; de Vos tot Nederveen Cappel 2004. Most 
studies showed that there was no benefit of 5FU based chemotherapy for MSI-H tumors, 
and in one study, there was even a trend towards a worse outcome for patients receiving 
5FU chemotherapy compared to those not receiving treatment. However, one prospective 
non-randomized trial concluded that for stage IV sporadic CRC, patients with an MSI-H 
tumor who received 5FU plus leucovorin chemotherapy had a better survival [Liang 
2002]. Due to the conflicting results found in these studies, prospective clinical trials are 
needed before definitive recommendations can be given regarding the effectiveness of 
chemotherapy in patients with MSI-H tumors [Vasen 2007a]. 
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2.7.4 Chemoprevention in Lynch Syndrome 
Data from observational studies and randomized clinical trials have demonstrated that the 
use of aspirin leads to a moderate reduction (20-30%) in the risk of sporadic colorectal 
adenomas and cancer [Baron 2003; Sandler 2003 ; Logan 2008]. A systematic review 
examining the benefits and harms of aspirin chemoprevention in average risk individuals 
found that the use of aspirin, especially if used in high doses for more than 10 years, 
reduces the incidence of colonic adenomas and CRCs [Dube 2007]. However, the data 
regarding a reduction in CRC incidence was inconsistent for cohort studies and 
randomized controlled trials. As well, the use of high dose aspirin increases the incidence 
of gastrointestinal complications, and as such, the possible harms should be considered. 
The use of resistant starch has also been suggested as a chemopreventative candidate fo r 
decreasing the risk ofCRC [Vasen 2007a]. 
A recent randomized, placebo-controlled trial evaluated the use of aspirin and resistant 
starch in reducing the risk of adenoma and carcinoma in LS mutation carriers [Burn 
2008] . They found no significant difference in neoplasia development between those who 
received aspirin compared to those who received a placebo (18.9% versus 19% 
respectively), nor did they find any significant difference between these groups with 
respect to the development of advanced neoplasia (7.4% vs. 9.9%, p=0.33). Similarly, no 
significant difference in neoplasia development was reported for those who received 
resistant starch compared to those who received placebo (18.7% versus 18.4 %, 
respectively). This study showed no benefit in terms of adenoma or CRC prevention in 
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LS patients due to the use of aspirin, resistant starch or both for up to 4 years. Longer-
term follow-up may be required to fully evaluate the use of aspirin chemoprevention in 
LS. 
The oral contraceptive pill has been shown to reduce the risk of both endometrial and 
ovarian cancer in the general population [Centers for Disease Control Cancer and Steroid 
Hormone Study 1983a, 1983b; Cancer and Steroid Hormone Study of the Centers for 
Disease Control and the National Institute of Child Health and Human Development 
1987] and also to prevent ovarian cancer in carriers of BRCAJ and BRCA2 mutations 
[McLaughlin 2007]. However, there are currently no data addressing the efficacy of 
chemoprevention in reducing gynecologic cancers in LS. 
2.8 NEWFOUNDLAND'S FOUNDER POPULATION 
The province of Newfoundland and Labrador, on Canada ' s east coast, has a unique island 
population that historically has been isolated from other parts ofNorth America. 
Although the first documented discovery of Newfoundland was in 1497 by John Cabot, 
permanent settlement was not established until around 1610. The peak immigration to 
Newfoundland occurred during the period 1780- 1830, and included mainly Protestant 
settlers from the south-west of England and Roman Catholic settlers from the south of 
Ireland [Mannion 1977]. 
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By the mid-1830' s, immigration decreased and the population ofNewfoundland was 
approximately 75,000. Thereafter, the population expanded rapidly to a peak of 580,000 
in the mid 1980' s due to a high birth rate. Approximately 90% of the current population 
can trace their origins to the 20,000 to 30,000 original settlers [Mannion 1977] . 
In addition to geographic isolation, coastal communities (outports) remained small and 
isolated until recently due to lack of roads, segregation by rel igion and limited 
immigration. Descendants of the original settlers frequently only moved to nearby coves 
or offshore islands which kept related families together. As a result of the way 
Newfound land was settled and expanded, Newfoundland's population is relatively 
homogeneous and consists of a series of genetic isolates [Parfrey 2002; Spirio 1999]. 
Approximately 55-60% of the population live in communities of <2,500 people and 40% 
in communities of < 1000 people [Rahman 2003 ; Woods 2005]. The current population of 
Newfoundland ( - 515,000) is a relatively new founder population ( <20 generations) with 
a limited number of founders [Rahman 2003]. The Newfoundland population is 
influenced by founder effects and a high coefficient of kinship and is an ideal region for 
the investigation of genetic diseases due to large fami ly size over the generations, close 
family ties to the ancestral communities, modest out-migration and a modern health care 
system [Parfrey 2002]. Of the 12 founder populations studied globally, Newfoundland 
has the greatest generalizability to other Caucasian populations [Service 2006] . 
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2.8.1 Founder Mutations in Lynch Syndrome 
Founder mutations are pathogenic mutations that are shared by apparently unrelated 
patients and are inherited from a common ancestor several or many generations 
previously. Founder mutations are characteristically introduced into a population due to a 
single mutation carrier, which over a period of generations, accounts for a large fract ion 
of the total disease burden in a specific population. Several features of a population, such 
as isolation (absence of significant immigration), rapid population growth, bottlenecks in 
population size and chance, increase the probability of a founder mutation prospering [de 
Ia Chapelle 2004]. 
Several found er mutations in MLHJ and MSH2 have been detected for LS, and in many 
of these populations, accounts for a sizeable proportion of all LS cases. Two founder 
mutations in MLHJ have been identified in the Finnish population and account for more 
than 60% of all disease-causing mutations identified in families with LS [Nystrom-Lahti 
1995; Moisio 1996] . A third founder mutation in MLH 1 was identified in the Valais 
region of Switzerland [Hutter 1996; Lynch 2004] . Founder mutations in MSH2 have been 
identified in the Ashkenazi Jews [Foulkes 2002], where it may account for as many as 
one third of all cases, and also in North Americans, where the mutation occurs with a 
high frequency in a large genetically heterogeneous population, spread over a wide 
geographic area [Lynch 2004] . 
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One of the first mutations identified causing LS was an intron 5 splice site mutation in 
MSH2 [Leach 1993]. A large Newfoundland kindred (Family C) was critical to the 
original study that allowed LS to be mapped to the short arm of chromosome 2p 
[Peltomaki 1993]. This work later led to the identification of an MSH2 germ line mutation 
in the 5' splice site of exon 5, resulting in deletion of exon 5 and a truncated protein [Liu 
1994] . This point mutation (MSH2 c. 942+ 3A ~ T) is the most common LS-associated 
mutation in the world and accounts for approximately 10% of all LS mutations 
worldwide [Desai 2000; de Ia Chapelle 2004]. Based on haplotype analysis, this mutation 
arises de novo in most cases, but in Newfoundland, all carriers of this mutation share a 
common haplotype and a common geographic origin, indicating a founder effect 
[Froggatt 1999; Desai 2000]. 
2.9 MSH2 MUTATIONS IN NEWFOUNDLAND 
As was previously stated, an intron 5 splice site mutation in the MSH2 MMR gene was 
the first LS-causing mutation to be identified in Newfoundland. This splice site mutation 
was first detected in a large Newfoundland family (Fami ly C) and was later found to be 
widespread through a founder effect. All additional families were independently 
ascertained and found to share a common haplotype and also a common ancestor from 
the same geographic region as Family C [Froggatt 1999]. 
Two other mutations in MSH2 have also been identified in Newfoundland. An exon 8 
deletion (c. l 277-? _ 1386+?del) has been identified in several families and haplotype 
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analysis suggests that this mutation arose from a common founder. The third mutation is 
an exon 4-16 deletion that segregates in a very large family (Family 11 ) and includes >80 
mutation carriers. All sibships with this mutation have been genealogically linked to a 
common founder. 
2.10 OBJECTIVES 
The main objectives of this thesis will be as follows: 
1. To determine whether the cumulative risk of cancer and mortality in a group of MSH2 
mutation carriers differs based on the specific mutation involved and whether gender 
differences in cancer and mortality outcomes is consistent across different mutations. 
2. To compare the incidence of CRC and overall survival for MSH2 mutation carriers 
who entered a colonoscopic screening program to that expected, derived from the non-
screened group, adjusting for gender and survivor bias. 
3. To compare gynecological cancer incidence and overall survival for female MSH2 
mutation carriers who received gynecological screening (case) and for matched controls, 
who were alive and disease-free at the age the case entered the screening program. 
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3.1 INTRODUCTION 
Colorectal Cancer (CRC) is the third most common cancer; after breast and lung cancer 
in women and after prostate and lung in men [Canadian Cancer Society 2004]. One of the 
most significant risk factors for CRC is family history [Lynch 2003; National Cancer 
Institute 2005]. Lynch syndrome (LS), often called hereditary non-polyposis colorectal 
cancer (HNPCC), is the most common hereditary CRC syndrome and is responsible for 
approximately 1 to 3 percent of cases of CRCs [Ponz de Leon 1999; Peel 2000; Salovaara 
2000; Cunningham 2001; Samowitz 200 1; Katballe 2002; Olsson 2003; Pinol 2004; de Ia 
Chapelle 2005 ; Sarroca 2005; Zhang 2005]. However, in Newfoundland up to 47% of 
CRC patients come from high-risk and intermediate-risk fami lies [Woods 2005]. 
Lynch syndrome is characterized by autosomal dominant inheritance, early age at onset 
of colorectal carcinoma, right-sided predominance, and increased incidence of 
synchronous and metachronous CRCs [Fitzgibbons 1987]. Additionally, extra-colonic 
cancers of the gastrointestinal tract, genitourinary tract, endometrium, ovaries, biliary 
tract, pancreas and brain are frequently observed [Mecklin 1991; Watson 1993; Aarnio 
1995 ; Lynch 1997; Vasen 1999]. 
Lynch syndrome has been associated with germline mutations in several DNA mismatch 
repair (MMR) genes, including MSH2, MLHJ, MSH6, and PMS2 [Syngal 2000; Wheeler 
2000]. Ninety percent of LS cases are caused by mutations in either MLH I or MSH2 
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[Peltomaki 1997; Lynch 2003, 2004]. Extracolonic malignancies are more frequently 
associated with mutations in MSH2 than with mutations in MLHJ [Rowley 2005]. 
Lynch syndrome shows incomplete penetrance (not all mutation carriers wi ll develop a 
cancer) and variable expressivity (individuals develop different cancers at different ages). 
In individuals with an MMR mutation, the lifet ime risk of developing CRC is about 80% 
[Watson 1993; Aarnio 1995; Peltomaki 1997; Wheeler 2000]. Endometrial and ovarian 
cancers occur in up to 60% and 10%, respectively, of female mutation carriers. Cancers 
such as gastric and urothelial cancers, also have a lifetime ri sk of about 10%, whereas 
other cancers occur in smaller proportions of mutation carriers despite a marked 
increased relative risk (3 to 25 times the risk of the general population) fo r some of them, 
e.g ., cancers of the small bowel and biliary system [Vasen 1996; Aarnio 1999; Berends 
200 1; Watson 200 1; Lynch 2004; Rowley 2005]. 
The province ofNewfoundland, Canada, has one of the most valuable populations for 
investi gating autosomal dominant diseases [Green 2002; Parfrey 2002; Hodgkinson 
2005]. Until very recently, little in or out migration had occurred since the founding 
immigrations from South East Ireland and South West England in the late 18th and early 
19th centuries. Large fam ilies were the norm over successive generations and fam ily 
members settled near the core community. 
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An extensive Newfoundl and family was used in the original study showing linkage 
between hereditary CRC and a locus on chromosome 2p [Peltomaki 1993). This later led 
to the identification of a germline mutation in MSI-12, c.942+ 3A>T, in the 5' splice site of 
intron 5, resulting in an inframe deletion of exon 5 in the mRNA [Liu 1994, 1996]. This 
mutation was subsequently found in a total of 12 Newfoundland families. The phenotypic 
expression of this founder MSJ-12 mutation was assessed and male mutation carriers were 
found to be at an increased risk for CRC and death from cancer when compared to female 
mutation carriers [Green 2002]. Further analysis of high risk families in ewfoundland 
and Labrador has led to the identification of two di fferent MSJ-12 mutations in six more 
families. These mutations include genomic deletions of exon 8 in fi ve fami lies and 
deletion of exons 4-16 in the sixth family. Tumors from these families do not express the 
MSH2 protein and exhibit microsatellite instability (MSI). 
The association between genotype and phenotype is poorly understood despite the fact 
that a large number of predisposing mutations have been identi fied [Peltomaki 200 I]. 
Whether there is a difference in cancer risk between carriers of the various MMR-gene 
mutations is unclear [Yasen 2001] . Based on current biochemical deduction, different 
mutations of the MSI-12 and MLJ-11 genes may be predicted to have diffe rent functional 
consequences [Peltomaki 200 I]. Consequently, assessment of the correlation between 
specific mutations (genotype) and their expression in family members (phenotype) is 
necessary [Terdiman 1999]. 
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The current study was undertaken to determine whether the phenotypic expression of 
Lynch syndrome, caused by mutat ions in MSH2, is influenced by the specific mutation 
and whether the effect of gender on cancer and mortality outcomes is consistent across 
families with different mutations. 
3.2 PATIENTS AND METHODS 
More than 300 families with high or intermediate risk for hereditary CRC have been 
referred to the Medical Genetics Program of Newfoundland. Fifty-two of these families 
met either the Am sterdam I or Amsterdam II criteria. Of these, eighteen families have 
been confirmed as having an MSH2 mutation. Informed consent was obtained from all 
subj ects or an appropriate proxy. Ethics approval was granted by the Human 
Investigations Committee of the Faculty of Medicine, Memorial Uni versity of 
Newfoundland, the Health Care Corporation of St. John' s and the Avalon Peninsula 
Health Board. 
3.2.1 Mutation Detection and Genotyping 
DNA from all available family members at 50% risk of inheriting an MSH2 mutation was 
prepared from whole blood using a simple salting-out method [Miller 1988]. The point 
mutation in the splice donor site ofintron 5 in MSH2 (c.942+3A>T) was determined by 
restriction fragment analysis as described previously [Froggatt 1995]. Ex on deletions in 
MSH2 were detected by Multiplex Ligation-dependent Probe Amplification (MLPA) 
using genomic DNA [Schouten 2002]. MLPA, using the HNPCC probes (kit # SALSA 
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P003), was conducted and analyzed according to the protocol provided by MRC-Holland 
(Amsterdam, Holland) on an ABI 377 Genetic Analyzer (Applied Biosystems, Foster 
City, CA). Genotyping, using microsatellite markers, for families segregating the exon 8 
deletion, was performed on either an ABI 3100 Genetic Analyzer (Applied Biosystems, 
Foster City, CA) or a Beckman Coulter CEQ 8000 Genetic Analysis System (Beckman 
Coulter Inc. , Fullerton, CA). Marker positions on chromosome 2 were identified using 
the Genome Browser from the UCSC Genome Bioinformatics website 
(http://genome.ucsc.edu/). Primer sequences were obtained from the Human Genome 
Database (http://www.gdb.org/). PCR protocols are available upon request. Alleles were 
called blind to affection status. 
3.2.2 Subjects 
At risk individuals were further classified as mutation carriers if they met one of the 
following criteria: i) confirmation by mutation testing, ii) obligate carrier (in the line of 
descent and having offspring with a proven mutation), or iii) in the line of descent and 
presenting clinically with an HNPCC tumor < 50 years of age. Individuals falling into the 
first two categories were called "mutation positive" while those in the last category were 
referred to as "presumed positive" . Information on family history, age of onset of clinical 
manifestations, type of cancer, and cause of death was collected from mutation positive 
or presumed positive family members and confirmed by medical records. 
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The study group consisted of 290 individuals from 18 families who had inherited an 
MSH2 mutation (Table 3.1). Twelve families with 151 mutation carriers had the intron 5 
splice site mutation (75 males and 76 females), five fami lies with 74 mutation carriers 
had the exon 8 deletion (37 males and 37 females) and one fami ly with 65 mutation 
carriers had the exon 4-16 deletion (31 males and 34 females). From these families , 235 
individuals (81 %) were found to be mutation positive (193 were confirmed by mutation 
testing to have an MSH2 mutation and 42 were labelled an obligate carrier), and the 
remaining 55 ( 19%) were considered presumed positive. 
Table 3.1 Characteristics of family members by type of MSH2 mutation 
Intron 5 Mutation Exon 8 Deletion Exon 4-16 Deletion 
N (%) N (%) N (%) 
Gender 
Males 75 (50) 37 (50) 31 ( 48) 
Females 76 (50) 37(50) 34 (52) 
Year of Birth 
Before 1930 39 (26) 18 (3 1) 16 (25) 
1930-1 969 98 (65) 36 (62) 43 (66) 
1970 and After 14 (9) 4 (7) 6 (9) 
Mutation Status 
Positive 125 (83) 60 (8 1) 50 (77) 
Presumed Positive 26 (17) 14 (19) 15 (23) 
Parent Carrier 
Mother 104 (69) 22 (30) 29 (45) 
Father 43 (28) 43 (58) 28(43) 
Unknown 4 (3) 9 ( 12) 8 (12) 
Cancer 
Yes 91 (60) 51 (69) 39 (60) 
No 60 (40) 23 (3 1) 26 (40) 
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3.2.3 Statistical Analyses 
Statistical analyses were done using version 11.5 of the Statistical Package for Social 
Sciences (SPSS). Chi-square tests were performed to determine if the distribution of 
specific cancer types (CRC, endometrial, ovarian, and transitional carcinoma of the 
ureter, bladder and renal pelvis) varied among the different mutation groups . Time to 
colorectal cancer, time to any first cancer, time to extracolonic HNPCC cancers 
(endometrial , ovarian, stomach and transitional cell carcinoma of the ureter, bladder and 
renal pelvis) and time to death were analyzed using the Kaplan Meier time-to-event 
analysis in mutation carriers. In the time-to-event analyses, mutation carriers were 
studied with respect to their risk of developing cancer from birth to death and lifetime 
risk was determined based on cumulative risk up to 70 years of age. Differences in 
survival curves for each mutation were tested for statistical significance using the log-
rank test. Relative risk of developing each outcome was estimated for male and female 
mutation carriers using the Cox Regression Model. Similar analyses were run on 
mutation positive carriers only, to determine if the ascertainment bias inherent in our 
selection criteria had an impact on our overall conclusions. For time-to-event analyses, 
the number at risk is less than the study population totals due to missing data on ages at 
cancer, death and last follow-up. 
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3.3 RESULTS 
3.3.1 Evidence for Founder Mutations 
All the sibships with the exon 4-16 deletion were genealogically linked to a common 
founder. It was not possible to genealogically connect the fi ve families segregating the 
exon 8 deletion but haplotype analysis (Table 3.2) strongly suggests that the mutation 
arose from a common founder in at least four of the five fami lies. Since this is a 
frequent ly identified mutation, [Bapat 1999; Wang 2003; Thiffault 2004] it may have 
arisen independently in family RO 134. However, the qter portion of the haplotype in thi s 
family is identical to that of the other four famil ies, therefore it is possible that this 
mutation has occurred but once in the Newfoundland population. Genealogical study and 
haplotype analysis have shown that eleven of the twelve families segregating the intron 5 
mutation likely have a common ancestor [Froggatt 1999]. 
Table 3.2 Haplotypes for mutation carriers in five fam ilies with an exon 8 deletion in 
MSH2. The marker order is pter-D2SJ 19-0.1 Mb-D2S2298-1.0 Mb-D2S21 74-0.9 
Mb-D2S2240-0.5 Mb-D2S391-0.8 Mb-D2S2227-0.4 Mb-MSH2-1.5Mb-D2S1247-2.2 
Mb-D2Sl 23-qter. 
R0004 R0014 R0134 R0165 R0457 
D2S119 2 14 2 14 222 2 14 2 14/2 16 
D2S2298 220 220 2 14 220 220 
D2S2174 277 277 277 277 277 
D2S2240 181 181 1771179 181 181 
D2S391 143 143 147 143 143 
D2S2227 2 14 214 206 2 14 2 14 
D2S1247 308 308 308 308 308 
D2S2739 242 242 242 242 242 
D2S123 209/211 209/2 11 209/21 1 209/21 1 209/2 11 
The marker order is pter-D2SJ J9-0.1 Mb-D2S2298- 1.0 Mb-D2S2174-0.9 Mb-D2S2240-0.5 
Mb-D2S391-0 .8 Mb-D2S2227-0.4 Mb-MSH2- 1.5Mb-D2Sl 247-2 .2 Mb-D2Sl23-qter 
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3.3.2 Comparison of Mutation Carriers 
Table 3.3 shows the di fferent types of fi rst cancers and overall tota l cancers for all 
mutation carriers. CRC was the fi rst manifestation of the disease in 54% of cases with the 
intron 5 splice site mutation, 59% of those with the ex on 8 deletion and 72% of those 
with the exon 4-1 6 deletion. For females, a large proportion of fi rst cancers were found to 
be cancers of the female reproductive system (endometrium, ovary and fallopian tube). 
Forty-nine percent of females with the intron 5 spl ice site mutation developed one of 
these cancers as did 33% of those with the ex on 8 deletion and 44% of those with the 
ex on 4- 16 deletion. After exclusion of presumed positive individuals the distribution of 
cancers was quite similar to that for a ll carriers. C RC was still the most prominent fi rst 
cancer and occurred in 51% of those with the intron 5 splice site mutation, 53% of those 
with the ex on 8 deletion and 75% of those with the exon 4-1 6 deletion. 
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Table 3 .3 Types of fi rst cancer and total overall cancers for each mutation N (%) 
Intron 5 Mutation Exon 8 Deletion Exon 4-16 Deletion 
Cancer Type (151 carriers) (74 carriers) (65 carriers) 
First Total First Total First Total 
cancer cancers cancer cancers cancer cancers 
CRC 49 (54) 81 ( 49) 30 (59) 52(47) 28 (72) 41 (57) 
Other HNPCC (Bethesda) 
Endometrial 14 (15) 22 (13) 6 (12) 10 (9) 7 (18) 8 (11) 
Ovarian 8 (9) 12 (7) 2 (4) 4 (4) 
Stomach 4 (5) 8 (5) 2 (4) 4 (4) 2 (3) 
Pancreatic 1(1) 
Ureter-TCC 3 (6) 6 (5) 5 (7) 
Renal-TCC 1 (1) 1 (2) 6 (5) 
Bladder-TCC 3 (2) 4 (4) 3 (4) 
Small bowel 1 (1) 4 (2) 1 (2) 1 (1) 
Fallopian tube 1 (1) 1(1) 
Non-HNPCC 
Prostate 5 (3) 1 (2) 3 (3) 
Skin3 9 (10) 17(10) 3 (6) 10 (9) 2 (5) 1 1 ( 15) 
Brain 2 (2) 2 (1) 
Breastb 1 (1) 3 (2) 1 (2) 6 (5) 
Cerv ix 2 (2) 2 (1) 1 (2) 1 (1) 
Retropharyngeal 1 (1) 
Multiple myeloma 1 ( 1) 
GI 2 (5) 2 (3) 
Spinal Cord 1 (1) 
Lung 2 (2) 
Liver 1 (1) 
TOTAL 91(1 00) 165(100) 51( 1 00) 110(1 00) 39(100) 72(1 00) 
TCC, transitional cell cancer; GI, gastrointestinal 
aMany of these skin cancers are part of the Muir-Torre Syndrome (keratoacanthomas) 
bThe higher rate of breast cancer in deletion 8 carriers seems likely to be linked to breast 
cancer in the family of a married-in individual and not the MSH2 mutation 
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Ofthe 151 mutation carriers with the intron 5 splice site mutation, 91 individuals (60.3%) 
developed at least one cancer. Forty-two of these individuals developed multiple cancers 
resulting in a total of 165 primary cancers for the 91 family members. Fifty-one 
individuals (68 .9%) with the exon 8 deletion had at least one cancer and twenty-five of 
these went on to develop additional cancers. A total of 110 cancers were found among the 
51 family members. For those with the exon 4-16 deletion, 39 family members (60%) 
were found to have at least one cancer. Eighteen individuals developed additional cancers 
resulting in a total of 72 cancers among the family members. 
3.3.3 Incidence of Cancer and Mortality 
The lifetime risk of developing cancer at any site for all MSH2 mutation carriers was 
found to be 94% (Table 3.4, Figure 3.1 ). These predisposed individuals were found to 
have a high lifetime risk of developing CRC (75%), transitional cell carcinomas (TCCs) 
of the ureter, bladder and renal pelvis (32%), and stomach cancer (1 4%). In females, 
lifetime risk for endometrial cancer was 58% and for ovarian cancer was 2 1%. Twenty 
percent of mutation carriers developed CRC before 40 years of age and 6% of female 
mutation carriers developed endometrial cancer before 40 years of age. Median life 
expectancy was 63 years. Across all cancer types, lifetime risk of cancer development 
was quite similar for those with a confirmed mutation (Figure 3.2) compared to all 
mutation carriers. 
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Table 3.4 Cumulative risk of cancer development in MSH2 mutation carriers 
Cumulative Any first Colorectal Endometrial Ovarian Transitional Stomach 
risk by age cancer cancer cancer cancer cell cancers cancer 
:s 30 5 4 0 0 0 0 
:s 40 27 20 6 3 0 2 
:s 50 66 47 25 11 1 4 
:s 60 86 65 49 18 8 6 
:s 70 94 75 58 21 32 14 
:s 80 99 79 58 21 32 14 
Mean 47 57 67 80 80 85 
Median 46 51 63 NA NA NA 
Events 176 119 40 16 20 12 
# at risk 276 278 141 141 275 275 
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Figure 3.1 Cumulative risk of cancer development in all MSH2 mutation carriers 
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Figure 3.2 Cumulative risk of cancer development in proven MSH2 mutation 
carriers 
Male carriers were found to have a significantly increased risk of developing any cancer 
(RR= l.4; 95% CI 1.0-1.9), of developing CRC (RR=2.9; 95% CI 2.0-4.2), and of death 
(RR=2.4; 95% CJ 1.6-3.6) compared with female carriers (Table 3.5, Figure 3.3a-c). 
Similar results were found for those considered mutation positive (Table 3.6). The risk of 
developing any first cancer (RR= 1.5 ; 95% CI 1.0-2.1 ), CRC (RR=2.5 ; 95% CI 1.6-3.9) or 
death (RR=2.3 ; 95% Cl 1.3-3.9) was significantly increased in male carriers compared to 
female carriers. 
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Table 3.5 Cumulative risk of cancer development or death for male and female 
mutation carriers 
Cumulative risk An~ first cancer Colorectal cancer Death 
by age Males Females Males Females Males Females 
:::: 30 9 2 8 1 6 2 
:::: 40 36 18 32 8 20 5 
:::: 50 71 60 65 30 37 11 
:::: 60 85 87 81 48 56 34 
:::: 70 95 94 88 61 84 53 
:::: 80 98 98 88 69 92 68 
Relative Risk 1.4 2.9 2.4 
(95% CI) (1.0-1.9) (2.0-4.2) (1.6-3.6) 
Mean 45 49 48 65 56 68 
Median 45 48 46 66 58 69 
Events 89 87 77 42 65 38 
# at Risk 134 142 136 142 135 141 
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Figure 3.3a Cumulative risk of cancer development for male and female mutation 
carriers (RR= l.4; 95% CI 1.0-1.9). 
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Figure 3.3b Cumulative risk of CRC development for male and female mutation 
carriers (RR=2.9; 95% CI 2.0-4.2). 
100 l 
·-c ·-., -'--, ----.. 
L. 
80 ~ 
' 
'--
'1. l l ~ \ ~ 
~ ~ 60 
'L ·~ l l 
:::l ~ en l_Female 
\!;! ~ j 40 \ :::l 
E Male 
:::l 
() 
20 l Ll 
0 
0 20 40 60 80 100 
Age at death or age at last follow-up (yrs) 
Figure 3.3c Cumulative risk of death for male and female mutation carriers 
(RR=2.4; 95% CI 1.6-3.6). 
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Table 3.6 Cumulative risk of cancer development or death for male and female 
mutation positive carriers 
Cumulative risk An~ first cancer Colorectal cancer Death 
by age Males Females Males Females Males Females 
~ 30 6 2 6 1 2 0 
~ 40 33 16 31 9 14 3 
~ 50 72 57 65 31 30 5 
~ 60 79 84 72 48 46 27 
~ 70 90 92 76 59 71 48 
~ 80 95 98 76 67 71 56 
Relative Risk 1.5 2.5 2.3 
(95% C!) (1.0-2.1) (1.6-3.9) (1.3-3.9) 
Mean 46 51 52 66 62 72 
Median 45 49 46 67 66 76 
Events 54 70 47 36 31 24 
# at Risk 99 124 I 01 124 100 123 
3. 3. 3.1 Impact of Mutation 
The cumulative probability of developing any first cancer, CRC, extracolonic cancers or 
death was compared for MSH2 mutation carriers with the intron 5 splice site mutation, 
the ex on 8 deletion and the exon 4-16 deletion. The age-related risk of any of these 
events was not significantly different for the three MSH2 mutations. There was, however, 
an increased number of transitional cell cancers of the ureter, bladder, and renal pelvis in 
those with the exon 8 deletion. Fourteen percent of total cancers in exon 8 deletion 
carriers were transitional cell cancers compared to 11 % in exon 4-1 6 deletion carriers and 
3% in intron 5 splice site mutation carriers (Table 3.3). Ten individuals with the exon 8 
deletion developed at least one transitional cell cancer compared to six individuals with 
the ex on 4-16 deletion and four with the splice site mutation (x2 = 8.6; P=.O 13). By age 
70 years, 44% of those with the ex on 8 deletion had developed one of these transitional 
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cell cancers as compared to 31 % of deletion 4-16 carriers and 16% of the splice site 
mutation carriers (Table 3. 7), but the difference did not achieve statistical significance. 
Table 3.7 Cumulative risk of developing transitional cell cancers of the ureter, 
bladder and renal pelvis in MSH2 mutation carriers 
Intron 5 
mutation 
Exon 8 Exon 4-16 All mutation 
Cumulative risk by age 
:s 50 
:s 60 
:s 70 
:s 80 
Mean 
Median 
Events 
# at Risk 
Relative Risk (95% CI) 
Exon 8 deletion versus intron 
5 mutation 
Exon 4-16 deletion versus 
intron 5 mutation 
Deletion carriers (ex on 8 and 
exon 4-1 6) versus intron 5 
mutation 
2 
5 
16 
16 
80 
NA 
4 
151 
deletion 
3 
6 
44 
44 
77 
NA 
10 
59 
2.8 (0.9-9.1) 
2.8 (0.9-8.3) 
deletion earners 
0 1 
16 8 
31 32 
31 32 
73 80 
NA NA 
6 20 
65 255 
2. 7 (0.8-9.5) 
A second analysis compared those with the splice site mutation and those wi th a genomic 
deletion (ex on 8 deletion and ex on 4-16 deletion combined). The age-related risk of 
developing any first cancer, CRC or death was not significantly different between the two 
groups. There was, however, a significantly increased risk of ovarian cancer for fam ily 
members with the splice site mutation (Table 3.8). Also, an elevated but not significant 
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risk for transitional cell cancers of the ureter, bladder and renal pelvis was found for 
deletion carriers. 
Table 3.8 Cumulative Risk of Developing Ovarian Cancer in Female MSH2 
Mutation Carriers 
Cumulative risk by age 
:s 30 
:s 40 
:s 50 
:s 60 
:s 70 
:s 80 
Mean 
Median 
Events 
Censored 
Relative Risk (95% CI) 
Splice site mutation versus 
genomic deletion 
Splice site Genomic 
mutation deletion 
0.0 0.0 
6.4 0.0 
17.1 4.6 
24.2 10.9 
31.8 10.9 
31.8 10.9 
72.7 84.6 
NA NA 
12 4 
64 61 
3.2 (1.0-10.1) 
All mutation 
earners 
0.0 
3.3 
11.2 
17.9 
21.2 
21.2 
80.3 
NA 
16 
125 
Similar results were found when the above analyses were repeated on those considered 
mutation positive only. Comparison of cumulative survival across the three MSH2 
mutations showed that there was no significant difference in time to development of any 
first cancer, CRC or death. However, when comparing the cumulative risk of 
extracolonic cancers, a significant difference was seen in time to development of 
transitional cell cancers of the ureter, bladder, and renal pelvis. The relative risk was 5.0 
(95% CI 1.1-23.3) for those wi th the exon 8 deletion compared to those with the intron 5 
splice site mutation, and for those with the ex on 4-16 deletion, the risk was 5.4 (95% CI 
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1.1-28.1 ) when compared to those with the splice site mutation. Comparing mutation 
positive individuals with a splice site mutation and those with a genomic deletion also led 
to similar results. Individuals w ith a genomic deletion were at a significantly increased 
ri sk for development of transitional cell cancers (RR=5.2; 95% CI 1.2-22.7) compared to 
those with the splice site mutation. Individuals with the splice site mutation, however, 
were found to have an increased risk for ovarian cancer compared to those with a 
genomic deletion but this did not achieve statistical significance (RR=2.6; 95% CI 0.8-
8.2). 
3. 3.3.2 impact ofGender 
There was no significant gender difference between time-to-development of any first 
cancer for carriers of the splice site and carriers of the deletion 8 mutations (Table 3.9). 
However, for those with the exon 4-16 deletion, the relative risk of any cancer 
development was 2.5 (95% C I 1.3-5.0) in male carriers compared with female carriers. 
Males were found to have a significantly increased risk of CRC development across all 
three MSH2 mutations (Table 3.9). For splice site mutation carriers, the ri sk of CRC in 
males compared to females was 2 .7 (95% C I 1.6-4.7) with 77% of males versus 40% of 
females developing the CRC by age 60 years. The re lative risk of C RC development was 
2.2 (95% Cl 1.1-4. 7) for males versus females with the ex on 8 deletion . Seventy-eight 
percent of males versus 45% of females developed CRC by 60 years. For those with the 
80 
ex on 4-16 deletion, the risk of CRC in males compared to females was 4.3 (95% CI 1. 9-
9.5). By age 60 years, 89% of males compared to 58% of females had developed CRC. 
Table 3.9 Cumulative risk of developing any 1st cancer, colo rectal cancer or death in 
male and female mutation carriers 
Any first cancer 
Events 
Number at ri sk 
Median age to I 51 cancer 
Relative riska 
95% CI 
Colorectal cancer 
Events 
Number at risk 
Median age to CRC 
Relative riska 
95% CI 
Death 
Events 
Number at risk 
Median survival 
Relative riska 
95% CI 
Intron 5 mutation 
Males Females 
44 47 
75 76 
46 47 
1.2 
0.8 - 1.9 
36 22 
75 76 
46 67 
2.7 
1.6 - 4.7 
3I 22 
75 76 
54 66 
2.1 
1.2-3.7 
a Compares males to females 
Exon 8 deletion 
Males Females 
22 24 
28 32 
46 46 
1.1 
0.6 - 1.9 
20 II 
30 32 
49 66 
2.2 
1.1 - 4.7 
20 9 
29 3I 
58 75 
3.1 
1.3-7.3 
Exon 4-16 deletion 
Males Females 
23 I6 
3 I 34 
4I 49 
2.5 
1.3-5.0 
21 9 
31 34 
42 59 
4.3 
1.9 - 9.5 
14 7 
3I 34 
63 77 
2.9 
1.1 - 8.2 
All fam ilies showed a significant gender difference for death, with males being at a 
greater risk for death than females (Table 3.9). In splice site mutation carriers, the 
relative risk of death was 2. 1 (95% CI 1.2-3 .7) for males versus females. The median 
survival was 54 years for males versus 66 years for females. The relative risk of death 
was 3. I (95% CI 1.3-7.3) for males with a deletion 8 mutation as compared to females 
8I 
with the same mutation, and the median survivals were 58 and 75 years, respectively. For 
those with an exon 4- 16 deletion, the risk of death for males compared to females was 2.9 
(95% CI 1.1-8.2). The median survivals were 63 years for males and 77 years for 
females. 
The previous analyses were also performed on mutation positive individuals only (Table 
3.1 0). Across al l 3 MSH2 mutations, the age-related risks for development of any first 
cancer were similar to the gender differences found for all mutation carriers . This was not 
true for time to CRC development or death. Only those with the splice site mutation and 
the exon 4-16 deletion showed a significant gender difference for CRC development, 
with males being at a greater risk than females. Also, only male carriers with the exon 8 
deletion were found to be at a significantly increased risk for death when compared to 
their female family members. 
3.4 DISCUSSION 
The penetrance of MMR gene mutations (lifetime cancer risk) has proven difficult to 
determine in LS cases and could be heavily dependent on the source of the reference 
sample [Carayol 2002; Hampel 2005b; Quehenberger 2005]. The results of our study 
cannot be directly compared to other penetrance studies, due to differences in methods of 
ascertainment, geographical variations in environmental factors, possible genetic 
modifiers and allelic heterogeneity, yet there are consistent find ings. 
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Table 3.10 Cumulative risk of developing any ts' cancer, colorectal cancer or death 
in male and female mutation positive carriers 
Intron 5 mutation Exon 8 deletion Exon 4-16 deletion 
Males Females Males Females Males Females 
Any first cancer 
Events 25 40 14 21 15 9 
Number at risk 56 69 20 28 23 27 
Median age to 1st cancer 45 48 46 52 45 59 
Relative riska 1.2 1.0 4.1 
95% CI 0.7-2.0 0.5-2.1 1.6-10.3 
Colorectal cancer 
Events 21 20 12 10 14 6 
Number at risk 56 69 22 28 23 27 
Median age to CRC 46 67 50 NA 45 59 
Relative riska 2.3 1.8 5.4 
95% CI 1.2 - 4.2 0.8 - 4.2 2.0- 14.8 
Death 
Events 13 15 12 6 6 .., _) 
Number at risk 56 69 21 27 23 27 
Median survival 68 68 58 69 69 80 
Relative risk3 2.0 3.2 3.3 
95% CI 0.9 - 4.3 1.1 - 9.0 0.7 - 16.2 
a Compares males to females 
Our lifetime CRC (75%) and endometrial cancer (58%) risk estimates are very similar to 
those reported in the literature. Most of these published risk estimates are derived from 
families collected at HNPCC registries and vary between 65-85% for CRC (Aarnio 1995, 
1999; Vasen 1996, 200 1] and 40-60% for endometrial cancer (Aarnio 1995 , 1999; Vasen 
1996; Dunlop 1997]. Similarly, our increased lifetime risks for ovarian, stomach, and 
transitional cell carcinomas of the ureter, bladder and renal pelvis are consistent with 
results from other published studies. In many cases however, our risk estimates are even 
higher than those reported especially for transitional cell cancers [ Aarnio 1995, 1999; 
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Yasen 2001]. We also found that CRC risk was higher in male mutation carriers than in 
female mutation carriers. This sex difference in CRC risk is in agreement with that 
reported by other investigations [Dunlop 1997; Aarnio 1999; Froggatt 1999; Yasen 2001] 
and is perhaps due to sex-linked modifier genes. Also, our findings for carriers of the 
intron 5 splice site mutation are consistent with those published previously. This mutation 
is one of the most frequently occurring mutations in HNPCC families worldwide [Liu 
1994, 1996; Froggatt 1995, 1999; Miyaki 1995; Pensotti 1997; Bai 1999; Chan 1999; 
Wang 1999; Desai 2000; Fidalgo 2000] with CRC being the most common cancer site, 
followed by endometrial and ovarian cancers for females [Miyaki 1995; Froggatt 1999] . 
Other infrequent cancer sites include skin and stomach cancer [Froggatt 1999]. Our 
penetrance estimates (up to 60 years of age) for any first cancer (89%), CRC (58%), 
endometrial cancer (53%) and our intersex differences in the lifetime risk of CRC (77% 
male vs. 40% female; P<.OO 1) are consistent with that reported elsewhere [Froggatt 
1999]. 
Studies have shown that there may be variation in the tumor spectrum depending on the 
specific MMR gene and mutation involved and the position of the mutation may be more 
important than the type [Aarnio 1999]. Therefore, it is possible that the intron 5 splice 
site mutation may have a functional consequence different than the genomic 
deletions,[Peltomaki 2001] although the MSH2 protein was not detectable on 
immunoassay for any of the three mutations. 
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An important consideration when performing genotype-phenotype studies is the 
underlying genetic background of the mutations. When trying to elucidate the phenotypic 
consequences of a particular mutation, studying a group of individuals with a very simi lar 
genetic background is preferred - as is the case when carriers of a specific mutation are 
members of the same extended family . We have demonstrated from genealogical study 
and haplotype analysis that each of the three MSH2 mutations identified in 
Newfoundland likely arose from a common ancestor. 
The lifetime probabilities of developing CRC were similar for all three mutations, as 
were the age-and gender-related risks. Transitional cell cancers of the urinary tract 
comprised a significantly lower proportion of cancers in carriers of the splice site 
mutation than in carriers of the genomic deletions. In addition, the incidence of ovarian 
cancer was higher in carriers of the splice site mutation. These observations may imply 
that the phenotypic expression of extracolonic cancers differs according to the type of 
MSH2 mutation, but care needs to be taken with this interpretation because of several 
limitations in this study. 
Although we have studied 290 mutation carriers, the number of extracolonic cancers is 
relatively small. In addition to small event rates, the likelihood of finding a false positive 
is quite high in this study because of multiple comparisons. Finally, the time-to-event 
analyses (Kaplan Meier and Cox Regression) do not take account of the possibility that 
clustering of events could occur in fami lies that may be unrelated to the MSH2 mutations. 
85 
For example, there may be other genetic variants in the family causing the development 
ofthese cancers, or lifestyle and environmental issues may be influencing the similarity 
of cancers found in these families. 
Another limitation is that carrier status was not confirmed in all family members by 
mutation testing. While the definition of an obligate carrier is reasonable, the genetic 
status of those at 50% risk who developed an HNPCC cancer before 50 years of age is 
less definiti ve. Kindreds identified in this manner, through family hi story, will inherently 
have a large number of CRC cases, and estimates of penetrance obtained in this manner 
may not be relevant to mutation carriers in the general population. Recent studies have 
suggested that current risk estimates for colorectal and endometrial cancers may be 
largely overestimated due to ascertainment bias introduced in the selection of families 
[Carayol 2002; Hampel 2005b; Quehenberger 2005]. However, after exclusion of 
presumed positive carriers, we found that our primary conclusions were the same: time to 
first CRC, first HNPCC cancer and death were similar in families with different 
mutations; type of mutation may have an impact on development of extracolonic cancers; 
and male gender was associated with a worse outcome. 
In this study three very large families , with three different mutations, have been 
ascertained in the same way. Confounding by environmental factors is likely to have been 
small because the families live in the same geographic area and have a similar cultural 
background. Clinical screening programs have been established, and to date, 1450 at risk 
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individuals have had at least one screening colonoscopy, and more than 70% of these 
have had multiple colonoscopies . The number of CRC and other cancer cases that this 
program has prevented will be investigated in a future study. 
In conclusion, the cumulative risk of developing cancer by 70 years is 94% in carriers of 
these MSH2 mutations. The age- and gender- related risks of CRC and death are similar 
for the exon 5 splice site mutation, the exon 4-16 deletion and the exon 8 deletion. There 
is evidence to suggest that transitional cell cancers of the urinary tract occur less 
frequently, and ovarian cancer in women occurs more frequently in carriers of the ex on 5 
splice site mutation than in carriers with these genomic deletions. 
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4.1 INTRODUCTION 
Lynch syndrome (LS), often called hereditary nonpolyposis colorectal cancer (HNPCC), 
is the most common hereditary colon cancer syndrome and accounts for 2-5% of all 
colorectal cancer (CRC) cases [Aaltonen 1998; de Ia Chapelle 2005 ; Hampel 2005a; 
Lynch 2009a]. This autosomal dominant disorder is characterized by early onset CRC, 
right-sided predominance, increased incidence of synchronous and metachronous CRCs, 
increased risk of other LS-associated malignancies [Mecklin 1991 ; Watson 1993; Aarnio 
1995, 1999; Lynch 2008a, 2009a] , and is caused by germline mutations in DNA 
mismatch repair (MMR) genes [Wheeler 2000; Lynch 2003]. 
The lifetime risk of developing CRC is about 70-80% in individuals with an MMR 
mutation [Vasen 1996; Aarnio 1999; Lynch 2000; Johnson 2006; Stuckless 2007; Barrow 
2008] and is influenced by sex, method of ascertainment and the MMR genes involved. 
The reported lifetime risks for CRC range from 27-1 00% in males and 22-83% in females 
[Vasen 1996, 200 1; Aarnio 1999; Hampel 2005b; Quehenberger 2005 ; Stuckless 2007; 
Barrow 2008 ; Ramsoekh 2009]. In Newfoundland MSH2 mutation carriers, females had 
a 39% lifetime risk of CRC compared with 85% in males, but females had a substantial 
risk of gynecologic cancers [Kopciuk 2009]. 
Screening with colonoscopy can potentially prevent the great majority of CRCs by 
detection and removal of adenomas, the precursors of most CRCs [Fletcher 2008]. 
Presently, screening for CRC in LS requires complete colonoscopy to the cecum every 1 
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to 2 years starting at ages 20 to 25 years, or 10 years younger than the youngest age of the 
person diagnosed in the family [Lynch 2000 ,2008a; Silva 2005 ; Lindor 2006]. 
In longitudinal studies of screening effectiveness, survivor bias favours screening when 
compared with those not screened. Furthermore, the phenotypic expression of MMR 
mutations is different in males and females [Green 2002; Stuckless 2007; Kopciuk 2009] , 
and higher enrollment and compliance with screening programs may also differ between 
males and females. A prior cohort study evaluated colonoscopic screening in LS and 
found that screening every 3 years decreased the C RC rate by 62% and decreased overall 
mortality by about 65% [Jarvinen 2000]. A more recent study showed that the median 
age at onset of CRC was delayed by more than 20 years in the screened group [Stupart 
2009]. However, no analysis by sex or adjustment for survivor bias was undertaken in 
these studies. 
This study was undertaken to determine the effectiveness of colonoscopic screening in 
male and female LS carriers of three different, phenotypically similar, MSH2 founder 
mutations. To correct for survivor bias we compared actual outcomes in the screened 
group with expected outcomes derived from the non-screened group, matching for age of 
entry to screening. Additionally, we determined compliance with screening 
recommendations and the relationship ofthe screening interval to CRC development in a 
subset of MSH2 mutation carriers. 
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4.2 MATERIALS AND METHODS 
Families with a known MSH2 mutation were initially identified through the Provincial 
Medical Genetics Program or the Department of Surgery at Grenfell Hospital, St. 
Anthony. Pedigrees were extended over time and the phenotype reported [Green 2002; 
Stuckless 2007]. Family members at 50% risk of inheriting a mutation were 
recommended to enter screening prior to discovery of the mutation, and carriers were 
recommended to do so fo llowing discovery of the mutation. Informed consent was 
obtained from all eligible subjects or an appropriate proxy. Individuals were considered 
eligible for the study if they were at 50% a priori risk to be mutation carriers and were 
included if they met one of the fo llowing criteria: 
1. Confirmation by mutation testing (Proven mutation carrier); 
2. In the line of descent and having offspring with a proven mutation (Obligate mutation 
carrier); 
3. In the line of descent and presenting clinically with a LS tumour < 50 years of age 
(Presumed mutation carrier). 
4.2.1 Eligible Participants vs. Study Participants 
On the basis of the above criteria, 387 individuals born after 1910 were considered to be 
eligible participants. Thirteen of these subj ects declined to participate, 39 were lost to 
fo llow-up and 13 were excluded because they did not return their consent form or 
because records were never received. Thus study subjects comprised 322 of 387 (83%) 
e ligible individuals ( 148 males, 174 females) belonging to 18 LS fam il ies. N ine fam il ies 
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had an intron 5 splice site mutation (c.942+ 3A/T), eight families had an exon 8 deletion 
(c. 1277-? _ 1386+?del) and one family had an ex on 4-16 deletion (c.646-? _ 2802+?del) 
(13 ). In total , 216 were proven mutation carriers, 50 were obligate mutation carriers and 
56 were considered presumed carriers. 
Screening for LS began in the late 1980s and initially included only colonoscopy every 1-
2 years starting at age 20-25 years. Of the 322 study participants, 152 ( 4 7%) entered a 
CRC screening program and the remaining 170 (53%) did not. The majority of those not 
screened had either had a prior CRC, and thus were not eligible as the study is limited to 
screening for first CRC, or died prior to implementation of the screening program. 
Individuals were considered to have entered a screening program if they had at least one 
colonoscopy prior to any symptoms suggestive of colorectal cancer. Median follow-up 
from entry into screening to death or last fo llow-up was 9 years in males and 11 years in 
females. 
To address compliance with screening recommendations, all colonoscopic information 
available for study subjects with an intron 5 splice site mutation and an exon 8 deletion 
were reviewed. Complete colonoscopy information following initial screening 
colonoscopy was not avai lable for those with an exon 4-16 deletion. A ll mutation carriers 
who had at least two colonoscopic examinations performed after I January 1994 were 
included. Eleven mutation carriers were excluded because they had only one colonoscopy 
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performed. Study subjects were considered compliant if all screening colonoscopies were 
performed within 2 years of the previous examination. 
4.2.2 Data Collection 
Medical records were reviewed and demographic data, dates and results of genetic 
testing, dates and results of various screening tests, dates and details of CRC, and 
mortality data were collected from 2006 to 2009. 
4.2.3 Statistical Analysis 
Survivor bias was shown by comparing the age of entry to screening in males and 
females with the age of onset of CRC in the non-screened group (Figure 4.1 a-b). Twenty 
eight percent of males screened entered the program after age 40 years, whereas by age 
40, approximately 50% in the non-screened group had already developed CRC. 
Comparable percentages for the females were 40% and 16%. To overcome this survivor 
bias in males, we compared the time to CRC and survival in the screened group to that 
expected from the non-screened group, where the expected outcome for each individual 
who entered a screening program was determined by calculating the median time-to-
event in non-screened individuals who were the same age and gender, alive and disease-
free , at the time the individual entered the screening program. For example, the expected 
survival for a 40 year old male who entered screening was the median survival of all 
males who survived to 40 years and were disease-free in the non-screened group. As 
survivor bias was less in females, and lifetime risk ofCRC is lower than in males 
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[Kopciuk 2009], we compared time to CRC in screened females with that in the non-
screened group. 
Statistical analyses were done using Version 15.0 of the Statistical Package for Social 
Sciences (SPSS). Cumulative incidences of CRC and death (all-cause mortal ity) were 
calculated using the Kaplan-Meier time-to-event analysis, and the significance of the 
difference between the groups was tested by the log rank test. Calculation of expected 
outcomes from the non-screened group fo r each screened individual assumed that the 
outcome would occur at a particular median age. This assumption is reasonable for CRC 
in men where penetrance is very high, and also for death in men and women, but may be 
less reasonable fo r CRC in women where the li fetime risk is lower. Therefore, the CRC 
comparison to expected outcomes was not performed for females. Median age at CRC 
diagnosis and median survival were based on Kaplan-Meier estimates and accounted for 
censored cases. Relative risk of developing each outcome was estimated for the screened 
group compared to that expected (deri ved from the non-screened group) using the Cox 
Regression Model. 
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Figure 4.1 a-b Age at entry into colo rectal (CRC) screening compared with age at 
diagnosis of CRC in non-screened group by gender [(a) males, (b) females]. 
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4.2.4 Ethics 
Ethics approval was granted by the Human Investigations Committee of the Faculty of 
Medicine, Memorial University ofNewfoundland. 
4.3 RESULTS 
Significantly more females than males entered screening (56% vs. 36%; x2= 12.6; 
P<.OO l ), with median age at screening being 36 and 38 years, respectively, for male and 
female mutation carriers . As anticipated, a predominance of the non-screened group was 
born between 1910 and 1950 (Table 4.1). Of69 males born after 1950, 46 (67%) entered 
screening, and of 87 females born after 1950, 70 (80%) did so (x2=3.84; P=.05 ). 
4.3.1 Outcomes in Non-screened Group 
In males, 79% developed at least one CRC with median age at CRC diagnosis being 41 
years, and in females, 55% developed CRC with median being 57 years. In males, 
median survival was 52 years, and 35 of 69 deaths (51%) were due to CRC. In females, 
median survival was 63 years, and 15 of 50 deaths (30%) were caused by CRC. 
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Table 4.1 Clinical characteristics of screened and non-screened group by gender. 
Males Females 
Non- Non-
Screened screened Screened screened 
n (%) n (%) p-value n (%) n (%) p-value 
Year of birth a 
1910- 1950 8 (15) 67 (74) 0.000 28 (29) 56 (77) 0.000 
After 1950 46 (85) 23 (26) 70 (71) 17 (23) 
Mutation Status 
Proven mutation carrier 50 (92) 37 (39) 0.000 96 (98) 33 (43) 0.000 
Obligate mutation carrier 2 (4) 26 (28) 1 (1) 21 (28) 
Presumed mutation carrier 2 (4) 31 (33) 1 ( 1) 22 (29) 
Colorectal cancer 
Yes 14 (26) 74 (79) 0.000 14 (14) 42 (55) 0.000 
No 40 (74) 20 (21) 84 (86) 34 (45) 
Dead 
Yes 4 (7) 69 (73) 0.000 7 (7) 50 (66) 0.000 
No 50 (93) 25 (27) 91 (93) 26 (34) 
MSH2 mutation 
Intron 5 splice site 30 (56) 54 (57) 0.967 59 (60) 43 (57) 0.129 
Exon 8 deletion 14 (26) 24 (26) 17 ( 17) 22 (29) 
Exon 4-16 deletion 10 ( 18) 16 ( 17) 22 (23) 11 (14) 
a Those with missing date of births were excluded 
4.3.2 Comparison of Outcomes after Screening to those Expected 
For screened males, median age to CRC was 58 years. Compared to the expected median 
age of 4 7 years derived from the non-screened group, screened males had significantly 
lower risks for CRC (RR=0.29; 95% CI 0.16-0.53) (Figure 4.2a). In screened females, 
median age to CRC was 79 years, substantially better than median age in the non-
screened group (RR=0.29; 95% CI 0.16-0.53) (Figure 4.2b ). 
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Median survival in males who entered screening was 66 years. Compared to the expected 
median survival of 62 years for males, those who entered screening had better survival 
(RR=0.38; 95% CI 0.13-1.0) (Figure 4.2c). For females, median survival in the screened 
group was 80 years compared to the expected median survival of 63 years (RR=O.l9; 
95% CI 0.085-0.44) (Figure 4.2d) . 
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Figure 4.2a. Lifetime risk of colorectal cancer (CRC) in screened male group 
compared with expected from non-screened males; b. Lifetime risk of CRC in 
screened female group compared with non-screened females 
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4.3.3 Compliance with Screening Recommendations 
Forty one males and 68 females in 16 families with the intron 5 splice site mutation and 
the exon 8 deletion had at least two colonoscopic examinations performed (Figure 4.3). 
Eighteen males ( 44%) and 28 females ( 4 1 %) were compliant with colonoscopy every 1-2 
years. 
Mutation Carriers 
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II 
Male Female 
41 68 
I I 
Compliant Non-Compliant Compliant Non-Compliant 
18 23 28 40 
CRC NoCRC CRC NoCRC CRC NoCRC CRC NoCRC 
6 12 5 18 4 24 6 34 
Interval <2yrs Interval > 2}TS l Interval <2yrs Interval >2yrs 
2 3 1 5 
Figure 4.3 Colorectal cancer (CRC) outcomes in mutation carriers with at least two 
colonoscopic examinations performed. 
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Eleven of 41 males (27%) developed an interval CRC, with median time from last 
screening colonoscopy to diagnosis being 1.7 years. Four individuals had a screening 
colonoscopy 1-2 years prior to their cancer diagnosis and four had screening within one 
year of their diagnosis (Table 4.2). Ten of 68 females ( 15%) developed an interval CRC, 
with median time from previous colonoscopy to diagnosis being 2.1 years. Four 
individuals had a screening colonoscopy 1- 2 years prior to their diagnosis and one was 
diagnosed at a screening interval less than one year (Table 4.2). 
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Table 4.2 Characteristics of screened mutation carriers with an interval cancer. 
Full 
Gender Age Stage Stage Intervalb colonoscopy Result of Cause of 
at Location (TNM) (Dukes) Compliane (years) at previous previous Dead Death 
CRC exam examination 
Males 
46c Proximal II B No 3.9 Yes Normal No 
53 Proximal I A No 1.8 Yes Normal No 
42 Proximal III c Yes 0.70 Yes Normal No 
50 Distal 0 No 1.7 Yes Normal No 
46 Proximal I A Yes 0.96 Yes Normal No 
58 Distal I A Yes 1.8 Yes Normal No 
52 Proximal II B No 3.9 Yes TA No 
43 Proximal 0 Yes 0.62 Yes Normal No 
38 Rectal III c Yes 1.4 Yes 2HP Yes CRC 
43 Rectal I A No 2.7 Yes TA& 7 HP No 
47 Distal II B Yes 0.65 Yes Normal No 
Females 
51 Proximal II B No 5.9 Yes Normal No 
43 Proximal II B Yes 0.22d Yes Normal No 
53c Proximal III c Yes 1.1 Yes Normal No 
79 Distal II B Yes 1.7 Yes Normal Yes Stomach Ca 
43 Proximal Ill c No 2.5 Yes Normal No 
43 Distal I A Yes 1.1 Yes TA No 
35 Distal 0 No 2.5 Yes Normal No 
64 Proximal A No 1.2 Yes UP No 
67 Proximal A No 5.2 Yes Normal No 
42 Proximal III c No 3.1 Yes Normal No 
39e Proximal I A 0.0 No 
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CRC, colorectal cancer; HP, hyperplastic polyp; TA, tubular adenoma; TNM, tumor, node, metastasis; UP, polyp with 
unknown histology 
aCompliant with current screening recommendations of colonoscopy every 1-2 years 
bTime from last colonoscopy to CRC development (years) 
clndividual had a double primary at diagnosis 
dlnvestigative colonoscopy: individual presented with fatigue and shortness of breath (had 2 prior colonoscopies 1 year apart 
that were normal) 
elndividual had CRC diagnosed on initial screening colonoscopy 
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4.4 DISCUSSION 
This is the first study to separately examine colonoscopy screening outcomes in male and 
female LS mutation carriers and to adj ust for survivor bias. In a group of genetically 
homogeneous families, it appears that colonoscopic screening prevented CRC and 
delayed the age at onset of CRC by more than 10 years fo r both male and female 
mutation carriers. It was associated with a 4-year improvement in li fe expectancy for 
males and a substantial improvement in life expectancy of more than 15 years for 
females. Further work on the impact of gynecological screening is ongoing to determine 
its contribution to the significant survival benefit found in female mutation carriers . 
In those born after 1950, men participated in screening less frequently than women. In a 
qualitative study, we have identified personal, health care provider and health care system 
factors as dominant issues in managing LS properly [Watkins 20 11 ). These factors may 
have a bigger infl uence on men than women, as barriers to effective screening behaviour. 
In the screened group, CRCs continued to occur even in those who were compl iant with 
co1onoscopy every 1-2 years. Only 44% of males and 4 1% of females had al l 
colonoscopies within 2 years of the previous examination. Twenty-one individuals 
developed an interval CRC, of whom eight had a colonoscopy 1- 2 years prior to their 
diagnosis. Similar results were reported from other studies of colonoscopic screening in 
LS mutation carriers: 13 of 34 interval CRCs were diagnosed within 2 years of a 
previously normal screening co lonoscopy [de Jong 2006a] and 16 of 33 CRCs in another 
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study [Vasen 20 I 0]. Given the high incidence of CRC and the accelerated adenoma-
carcinoma sequence in LS [de Jong 2004b ], annual screening colonoscopies may be 
appropriate for this group. 
In our study, five compliant individuals developed CRC within 1 year of their previous 
colonoscopy. In another study, 19 of 43 interval cancers detected by screening were 
preceded by a normal colonoscopic exam within the recommended interval of 12 months 
[Engel 20 1 0]. This must question the quality of the colonoscopic examination as these 
tumours were likely to have been missed lesions. Studies have shown that the adenoma 
miss rate in LS carriers with conventional colonoscopy is more than 50%, and that many 
of these missed lesions are small , flat adenomas [Hurlestone 2005; Lecomte 2005; East 
2008; Stoffel 2008]. Given the accelerated carcinogenesis in LS, improved detection of 
small lesions may be very important. Comparison of back-to-back examinations, in 
which standard colonoscopy was fo llowed by chromoendoscopy, chromoendoscopy 
substantially increased the number of adenomas detected in individuals with LS 
[Hurlestone 2005 ; Lecomte 2005; Stoffel 2008] , as did standard colonoscopy with 
intensive inspection (lasting > 20 minutes) [Stoffel 2008], narrow band imaging [East 
2008] and autofluorescence endoscopy [Ramsoekh 201 0]. It is likely that prevention of 
CRC in LS wi ll be more effective with better colonoscopic imaging technologies. 
Several limitations may be associated with cohort studies ofthis type. We have shown 
that direct comparison of screening outcomes with outcomes in the non-screened group 
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favours the screening intervention, as only survivors without CRC can enter the screening 
program . In fact, median survival in all the non-screened males was 52 years, whereas 
expected survival in the non-screened males derived from those matched by the age of 
entry to the screening program was 62 years. Furthermore, the bias associated with the 
majority of the non-screened group being historical controls also favours the screening 
intervention, as does volunteer bias, as subjects who agreed to undergo colonoscopic 
screening may have been in better health than those who were not screened. This was a 
retrospective study, and compliance rates may be underestimated if colonoscopy reports 
were missed. Finally, median fo llow-up was 9 years in men and 11 years in women, 
probably not long enough to evaluate the long-term outcomes of screening, particularly 
as the number who survived longer than 60 years in the screened group was small. 
In conclusion, the colonoscopic screening program in MSH2 mutation carriers reduced 
the incidence of CRC and improved survival, but potential sti ll ex ists to obtain better 
outcomes by improving compliance, reducing the colonoscopy screening interval to 1 
year, and enhancing the quality of colonoscopy examination. 
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5.1 INTRODUCTION 
Lynch syndrome (LS) is an autosomal dominant syndrome caused by germline mutations 
in DNA mismatch repair (MMR) genes [Lynch 2009a]. For female mutation carriers, the 
lifetime risk of developing endometrial cancer is estimated to be 30-70%, which equals or 
exceeds their risk of colorectal cancer (CRC) [Hendricks 2004; Hampel 2005b; Stuckless 
2007; Barrow 2009], and may vary depending on the MMR gene involved [Hendricks 
2004; Senter 2008; Barrow 2009; Ramsoekh 2009]. Lifetime risk estimates for ovarian 
cancer vary from 6% to 20% [Hampel 2005b; Stuckless 2007; Barrow 2009]. 
Current recommendations for gynecologic screening in LS require endometrial biopsy, 
transvaginal ultrasound (TVU) and CA 125 testing, every 1-2 years starting at ages 30-35 
years [Lindor 2006; Schmeler 2008; Lynch 2009a; Meyer 2009; Auranen 20 11]. The 
benefit of screening for gynecological cancers in LS, however, has not yet been proven 
and there is also no consensus on the optimal screening tests to be performed 
[Manchanda 2009; Auranen 2011]. Endometrial cancer screening may have limited 
benefit because of early detection of disease due to postmenopausal vaginal bleeding and 
high survival rates following diagnosis. Screening for ovarian cancer in other high-risk 
groups has not led to early cancer detection using TVU and CA 125 testing or improved 
survival [Evans 2009]. 
We recently evaluated colonoscopic screening in male and female LS mutation carriers 
with three different founder MSH2 mutations [Stuckless 20 12], between which there was 
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little phenotypic difference [Stuckless 2007]. After adjustment for survivor bias, we 
found that colonoscopic screening was associated with a 4 year improvement in life 
expectancy for males and a substantial improvement of more than 15 years for females 
[Stuckless 20 12]. However, the contribution of screening for gynecological cancers in 
female mutation carriers to this improvement was unknown. This study was undertaken 
to compare the incidence of endometrial and ovarian cancer and overall survival in 
carriers who entered a screening program for gynecologic cancer and in matched controls 
who were not screened. 
5.2 MATERIALS AND METHODS 
Seventeen families with one ofthree known MSH2 founder mutations were identified 
through the Provincial Medical Genetics Program or the Department of Surgery at 
Grenfell Hospital , St. Anthony. Eight families had an intron 5 splice site mutation 
(c.942+3A/T), eight an exon 8 deletion (c.l277-?_ 1386+?del) and one an exon 4-16 
deletion ( c.646-? _ 2802+?del) [Stuckless 20 12]. In the early 1990s, all family members at 
50% risk of inheriting a mutation were recommended to enter screening prior to 
discovery of the mutation, and carriers were recommended to do so fol lowing discovery 
of the mutation. All female mutation carriers, born after 1910, were identified and 
informed consent was obtained from all eligible subjects or an appropriate proxy. 
Individuals were considered el igible for the study if they were at 50% a priori risk to be 
mutation carriers and fulfilled one of the fo llowing criteria: 
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1. confirmation by mutation testing (Proven mutation carrier); 
2. in the line of descent and having offspring with a proven mutation (Obligate mutation 
carrier); 
3. in the line of descent and presenting clinically with a LS tumour < 50 years of age 
(Presumed mutation carrier). 
5.2.1 Eligible participants vs. Study participants 
Based on the above criteria, 204 females were considered to be eligible participants. 
Thirty (15%) subjects were excluded because they either declined to take part in the study 
(n=7), their records were never received (n=9), or they were lost to follow-up (n= 14). Of 
the 174 included in the study, 129 were proven mutation carriers, 22 were obligate 
mutation carriers and 23 were presumed mutation carriers. 
Individuals were considered to have entered a gynecological screening program if they 
had at least one gynecological examination (TVU, endometrial biopsy orCA 125 test) 
prior to any symptoms suggestive of endometrial or ovarian cancer. Screening for 
endometrial cancer was carried out using TVU and endometrial biopsy and screening for 
ovarian cancer was performed using TVU and CA 125 testing. 
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5.2.2 Data Collection 
Dates and results of genetic testing, screening tests, cancer onset and death were collected 
between September 2006 and January 2010. FIGO stage was also collected for cases and 
matched contro ls. 
5.2.3 Statistical Analysis 
Survivor bias is inherent in screening studies of this type as only those who are alive and 
disease-free can enter a screening program (Figure 5.1 ). To overcome this bias, we 
compared time to event outcomes in the screened group (case) to matched controls in the 
non-screened group, taking into account age at entry into the screening program. One 
control was randomly selected for each case from all non-screened individuals who were 
alive and disease free, at the same age as the case at entry into the screening program. 
Cumulati ve incidences of gynecological cancer and all-cause mortali ty were calculated 
using the Kaplan-Meier time-to-event analysis, and the significance of the difference 
between groups was tested by the log rank test. Individuals were censored at date of 
gynecological cancer, hysterectomy and bilateral oophorectomy, death or last follow-up. 
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Figure 5.1 Age at entry into gynecological screening compared with age at diagnosis 
of gynecological cancer in the non-screened group 
5.2.4 Ethics 
Ethics approval was granted by the Human Investigations Committee of the Faculty of 
Medicine, Memorial University ofNewfoundland . 
5.3 RESULTS 
Fifty four of 174 (3 1 %) female MSH2 mutation carriers had at least one gynecological 
screening exam and 120 did not. Median age at screening was 36 years wi th 6 1% of 
females screened by the age of 40 years. Thirty nine percent of females were screened 
after 40 years by which time 12% of the non-screened group had already developed 
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gynecological cancer (Figure 5.1). Median follow-up from entry into gynecological 
screening to death or last follow-up was 8.5 years 
5.3.1 Non-Screened Group Outcomes 
Fifty-five of 120 (46%) women in the non-screened group developed a gynecological 
cancer (Table 5.1), with median age to gynecological cancer being 60 years (Figure 5.1) . 
There were 54 deaths with 11 due to endometrial cancer and five to ovarian cancer. Mean 
survival was 66 years. Four ofthe II women who died of their endometrial cancer died 
within one year of their diagnosis, and eight within the first three years. Three of the five 
women who died of ovarian cancer died within one year of their diagnosis. Six of the 11 
deaths from endometrial cancer occurred before 1990 as did two of the fi ve deaths from 
ovanan cancer. 
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Table 5.1 Clinical characteristics of female MSH2 mutation carriers by 
gynecological screening status 
Screened Non-screened Matched 
group (cases) group contro ls 
n (%) n (% ) n(%) 
Year of birth" 
19 10-1 950 8 ( 15) 76 (65) 44 (8 1) 
After 1950 46 (85) 4 1 (3 5) I 0 ( 19) 
Mutation status 
Proven mutation carrier 53 (98) 76 (64) 36 (67) 
Obligate mutation carrier 0 (0) 22 ( 18) I 0 ( 18) 
Presumed mutation carrier I (2) 22 ( 18) 8 ( 15) 
Gynecological cancerb 
Yes 14 (26) 55 (46) 25 ( 46) 
No 40 (74) 65 (54) 29 (54) 
FIGO stagec 
Localized (Stage I & If) II (92) 12 (7 1) 
Advanced (Stage III & IV) I (9) 5 (29) 
Endometrial cancer 
Yes 9 ( 17) 44 (3 7) 20 (37) 
No 45 (83) 76 (63) 34 (63) 
Ovarian cancer 
Yes 6 ( I I ) 16 ( 13) 6 ( I I) 
No 48 (89) I 04 (87) 48 (89) 
Colorecta l cancer 
Yes 8 ( 15) 48 (40) 24 (44) 
No 46 (85) 72 (60) 30 (56) 
Gynecologica l surger/ 
Hysterectomy w ith BSO 8 ( 15) 14 ( 12) 6 ( I I) 
Hysterectomy w ith RSO 0 (0) 2 (2) 2 ( 4) 
Hysterectomy w ith LSO 0 (0) I ( I ) 0 (0) 
Hysterectomy 4 (7) 9 (8) 7 ( 13) 
Dead (all -cause morta li ty) 
Yes 3 (6) 54 (45) 29 (54) 
No 5 1 (94) 66 (55) 25 (46) 
Death due to gyne cancer 
Yes 2 (67) 16 (30) 6 (21) 
No I (33) 38 (70) 23 (79) 
BSO, bilate ra l salp ingo-oophorectomy; RSO/LSO, right/ left salpingo-oophorectomy 
"Those w ith missing date of births were excluded 
b T hose w ith both an endometria l and ovarian cancer were counted only once 
P-value 
(cases vs . 
contro ls) 
0.000 
0 .000 
0 .028 
0 . 168 
0.0 17 
1.000 
0.00 1 
0.246 
0.000 
0.080 
c FIGO stage fo r gynecological cancers (endometria l and ovarian cancers combined); Those with 
missing FIGO stage were excluded 
d T hose who had gynecological surgery performed prophy lactically or for non-ma lignant 
condit ions 
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5.3.2 Screened Group Outcomes 
Fourteen of 54 (26%) women in the screened group developed at least one gynecological 
cancer (Table 5.1 ). Nine females had endometrial cancer diagnosed, five of which were 
within one year of a prior negative screening test and two were at initial screening test. 
Of the nine endometrial tumors, seven were localized cancers (all Stage I), one was at an 
advanced stage (stage III) , and staging was unavailable for one (Table 5.2). No deaths 
were due to endometrial cancer. Six females had ovarian cancer detected, three of which 
were diagnosed within one year of a prior negative screening test. All four ovarian 
tumors with available staging information were localized tumors (Stage IIII). However, 
of the three deaths in the screened group, two were due to ovarian cancer. One died 
within I year of her ovarian cancer diagnosis and the other within two years (Table 5.2). 
5.3.3 Comparison of Outcomes After Screening to Matched Controls 
Of the 54 randomly selected matched controls, 25 ( 46%) developed at least one 
gynecological cancer (Table 5.1). Median age to gynecologic cancer in the screened 
group versus the control group was not significantly different (54 years versus 56 years; 
P= .50) (Figure 5.2a). In the control group, 12 of 17 (7 1 %) had localized tumors (s ix 
stage I, six stage II) and five were at an advanced stage (two stage III , three stage IV). 
Staging was unavailable in eight. Although 92% of cancers diagnosed in the screened 
group were localized compared to 71 % in the control group, this difference did not 
achieve statistical significance (Table 5.1). 
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Table 5.2 Characteristics of screened m utation carriers who developed endometrial or ovarian cancer. 
Result of Follow-
Age at Screen Type of last Interval previous up Cause of 
Study ID Stage detected3 • b (years)c (years)d Dead death cancer screenmg exam exam 
Endometrial Cancer 
152e 50 1a No TVU 0.98 Normal 0.92 Yes Ovarian Ca 
186f 47 3a Yes 5.45 No 
17 46 1a Yes TVU/Endo Biopsy 5.76 Normal 7.84 No 
74 54 la Yes TVU/Endo Biopsy 1.00 Abnormalg 12.93 No 
203 48 1b No TVU 0.47 Normal 6.36 No 
224 53 N/A No Endo Biopsy 0.87 Normal 0.55 No 
590f 37 1a Yes 9.68 No 
723 40 la No TVU 0. 12 Normal 8.86 No 
735 41 1a Yes Endo Biopsy 1.04 Normal 4.09 No 
Ovarian Cancer 
152e 50 2c No TVU 0.98 Normal 0.92 Yes Ovarian Ca 
29 50 2c Yes TVU 0.94 Normal 8.36 No 
507 45 la No Endo Biopsy 1.56 Normal 3.80 No 
518 38 2b No TVU 1.06 Abnormal11 5.83 No 
761 37 N/A No Endo Biopsy 0.46 Normal 1.12 Yes Ovarian Ca 
PID=205 82 N/A N/A N/A N/A N/A 0.69 NIA 
TVU, transvaginal ultrasound; N/A, not available 
3 Cancer was detected on a screening exam 
bLast screening exam (TVU, Endometrial biopsy or CA 125) prior to cancer diagnosis 
cTime from last screening exam to cancer development (years) 
dFollow up is from cancer diagnosis to last fo llow-up or death 
elndividual had a double primary at diagnosis (endometrial and ovarian cancer) 
rlndividual had endometrial cancer diagnosed on initial screening exam 
gTVU and endometrial biopsy show possible endometrial hyperplasia 
hTVU showed cyst in right ovary 
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to matched controls in the non-screened group; b. Lifetime risk of death in screened 
group compared to matched controls in the non-screened group 
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There were 29 deaths in the matched control group, six of which were due to a 
gynecological cancer (Table 5.1). Mean survival was substantially better in the screened 
group compared to matched controls but did not achieve statistical significance (79 years 
versus 69 years; P =.ll) (Figure 5.2b ). Three of six deaths in the matched control group 
were due to an endometrial cancer and three were due to an ovarian cancer. Of those who 
died due to endometrial cancer, one had stage IIA disease, one had stage IIIB disease and 
one was of unknown stage. For those who died due to ovarian cancer, one had stage I 
disease, one had stage IV disease and one was of unknown stage. 
5.3.4 Impact of Endometrial and Ovarian Cancer Screening 
For the endometrial screened group, median age to endometrial cancer was 54 years 
compared to 57 years in matched controls (P=.77) (Figure 5.3a). In the ovarian screened 
group, three cancers were detected, all by age 50 years, with no difference in the 
cumulative incidence of ovarian cancer in the two groups (Figure 5.3b). 
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5.3.5 Impact of Colonoscopic Screening 
Fifty one of 54 (94%) women in the gynecological screened group also entered 
colonoscopic screening. However, 47 of 120 (39%) women in the non-screened group 
had colonoscopic screening but could not enter gynecologic screening. This was due to 
the fact that these women had already had either a gynecologic cancer (n= l 5), a 
hysterectomy with or without ovaries removed due to a non-malignant condition (n=2 1), 
or were less than 30 years of age at last fo llow-up and had not yet reached the start age 
for gynecological screening (n=6). In five women the reason was unknown. For those 
who received both gynecologic and colonoscopic screening, median age to CRC was 
significantly higher (82 years versus 60 years; ? =.009) and mean survival was 
substantially better (78 years versus 67 years; ? =.08) than that in matched contro ls 
without any screening. 
5.4 DISCUSSION 
Despite the substantially increased risk of endometrial and ovarian cancer for female 
MSH2 mutation carriers, gynecological cancer screening did not result in earlier 
diagnosis of gynecologic cancer. This may be due to the fact that gynecological cancers 
in LS appear to present at an early stage regardless of screening status [Boks 2002; 
Crijnen 2005 ; Grindedal 20 1 0]. Interval cancers were also detected despite screening. 
Eight of 15 gynecological cancers were diagnosed within one year of prior screening 
suggesting that the methods for gynecologic screening were limited . 
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In the total non-screened group of female MSH2 mutation carriers, gynecologic cancer 
occurred frequently and both endometrial and ovarian cancer contributed to the poor 
survival. Cancer was likely diagnosed at a later stage because eight of 11 endometrial 
cancer deaths occurred wi thin three years of diagnosis and three of five ovarian cancer 
deaths occurred within one year of diagnosis. However, in the matched control group, of 
the four gynecological related deaths with available staging, two deaths occurred after 
diagnosis of a localized tumor and two occurred in those diagnosed at an advanced stage. 
This is similar to a study that found that 50% of women with an MMR mutation who died 
within the fi rst three years of their ovarian cancer diagnosis had stage I or II disease 
[Grindedal 201 0] . 
None of the nine women in the screened group diagnosed with endometrial cancer died 
but two deaths at a young age were attributable to ovarian cancer. Given the fact that 
these two women died quickly after their diagnosis and that in both women the cancer 
was diagnosed within a year of prior screening, the option of risk-reducing hysterectomy 
and bilateral salpingo-oophorectomy should be recommended for women who have 
completed childbearing [Schmeler 2006]. In our study, if women had undergone 
prophylactic surgery at the age of 40 years, over 70% of gynecological cancers might 
have been prevented. Compared to annual gynecologic screening and annual examination 
prophylactic surgery is the most cost-effective strategy, regardless of the starting age of 
any ofthe three strategies [Chen 2007; Kwon 2008; Yang 2011]. However, as the age at 
first screening increases, the cost-effectiveness advantage rapidly diminishes and 
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therefore women are recommended to have prophylactic surgery as early as possible, 
particularly after completion of child-bearing. 
Being part of a surveillance (screening) program, not the actual gynecologic screening 
procedures themselves, likely contributed to the longer life expectancy in those who had 
gynecological screening. In particular, colonoscopic screening prevented CRC and 
contributed at least in part to the improved survival in the screened group [Stuckless 
20 12]. 
Our study is limited by its retrospective nature and its use of historical controls in the 
non-screened group. Prior to 1990, cancer risk in these families may not have been well 
established, which likely predisposed to later stage of cancer at diagnosis. Lack of proper 
nutrition, health care and management of advanced disease may have contributed to poor 
outcomes. However, the use of historical controls should lead to bias in favor of 
screening in studies of this type. Survivor bias also favors screening and we have 
adjusted for this bias by selecting appropriately age matched controls. Although we 
report on re latively small numbers and short fo llow-up, this paper suggests that screening 
for gynecologic cancer did not contribute to the virtual normalization of life expectancy 
in screened female carriers. Future studies with longer fo llow-up and more patients may 
be necessary to evaluate the long-term outcomes of screening. Gynecologic screening of 
women in their fourth decade and those who chose not to have prophylactic gynecologic 
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surgery requires further evaluation, particularly as there was a trend towards diagnosis of 
gynecologic cancer at an earlier stage in the screened group. 
In conclusion, screening for gynecological cancer in female LS mutation carriers did not 
result in earlier diagnosis of gynecologic cancer and interval cancers occurred. The 
occurrence of both ovarian cancer deaths at a young age in screened patients and 
gynecological cancer deaths despite early stage disease in matched controls suggests that 
prophylactic hysterectomy and bilateral salpingo-oophorectomy should be performed in 
women who have completed childbearing. 
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CHAPTER 6 
Discussion 
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6.1 INTRODUCTION 
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths in Canada. 
Of the common cancers, CRC has the highest potential for prevention through detection 
and removal of adenomas by screening colonoscopy [Fletcher 2008]. Detection of CRCs 
at an earlier stage and more effective treatments can improve morbidity and mortality. 
Therefore it is important that those at high risk for CRC be identified so that they can 
receive appropriate colonoscopic screening. Newfoundland has the highest incidence of 
CRC and highest rate of CRC death in Canada, and the highest rate of familial CRC in 
the world. In Newfoundland, approximately 30% of incident CRC cases have at least one 
first degree relative affected with CRC [Green 2007]. Four percent of these incident cases 
have monogenic disease of known etiology, such as Lynch syndrome (LS), 8% have a 
high risk family history but no known genetic cause of CRC has been identified, and 18% 
have familial CRC but do not meet the high risk criteria for known hereditary CRC 
syndromes. Those with high risk family histories for CRC have a lifetime cancer risk of 
40-50% or more and those with at least one first or second degree relative with CRC have 
a predicted lifetime risk of CRC of approximately 20%. Therefore, accurate assessment 
of familial risk is necessary and allows for directed colonoscopic screening. 
6.2 IMPACT OF SCREENING IN MSH2 MUTATION CARRIERS 
Among those with high risk family histories, LS is the most common hereditary CRC 
syndrome. Due to the young age at onset and high penetrance of CRC in LS families and 
the significantly increased risk of gynecological cancers for female mutation carriers, 
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early identification of mutation carriers is necessary to prevent and reduce cancer-related 
morbidity and mortality associated with this disease. 
In chapter three we looked at the phenotypic expression of MSH2 mutation carriers in 
Newfoundland and found that male mutation carriers had a significantly increased 
lifetime risk of CRC compared to female mutation carriers. This gender difference was 
consistent across the three different founder MSH2 mutations reported in our study. 
Female mutation carriers were also found to have a high lifetime risk of developing both 
endometrial and ovarian cancer. Our significantl y increased risks for CRC and 
gynecological cancer are consistent with published reports of high lifeti me risk of CRC 
and increased extracolonic cancer incidence for MSH2 mutation carriers [Vasen 1996; 
Dunlop 1997; Aarnio 1999; Vasen 2001 ; Hampel 2005b; Barrow 2008, 2009; Ramsoekh 
2009]. 
Identification of LS mutation carriers and an accurate description of the natural history 
and penetrance of disease are necessary to provide a rational and directed screening 
program. Individuals found to have LS will require intensive surveillance whereas those 
without the mutation will not. In chapter 4 we evaluated the impact of colonoscopic 
screening in male and female MSH2 mutation carriers, adjusting for surv ivor bias. As 
discussed in chapter 4, colonoscopic screening was found to significantly reduce the risk 
and delay the age of CRC onset for both male and female mutation carriers. More 
importantly, colonoscopic screening was associated with a significant improvement in 
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life expectancy for males and a substantial improvement of more than 15 years for female 
mutation carriers. Our study supports the previous work by Jarvinen et al. [Jarvinen 
2000] and Stu part et al. [Stupart 2009] of a reduced risk of CRC and improved survival 
for LS mutation carriers who receive colonoscopic screening, and also provides novel 
information regarding the benefit of colonoscopic screening for male and female 
mutation carriers separately. 
Although colonoscopic screening has been shown to reduce the risk of CRC 
development, CRCs are still occurring in individuals compliant with the screening 
recommendation for LS of colonoscopy every 1 to 2 years. In our study, 13 of 21 
individuals who developed an interval CRC had a screening colonoscopy within two 
years of their CRC diagnosis (Chapter 4). This is consistent with results from other 
published studies that report interval CRCs in LS mutation carriers within 2 years of a 
previously normal colonoscopic exam [de J ong 2006a; Vasen 20 1 0]. Given the 
accelerated carcinogenesis in LS and the relatively high incidence of CRC in screened 
subjects, it has been proposed that the screening interval be shortened to one year [Lynch 
2008a; Engel 20 I 0]. To identify the most optimal screening interval, future prospective 
large-scale controlled trials are needed to compare cancer and mortality outcomes in 
those with 1 to 2 year screening intervals and those with 1 year intervals. 
Colorectal cancer screening in LS is generally performed using conventiona l 
colonoscopy, however, studies have shown that the adenoma miss rate is more that 50% 
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in this group and that many of these missed lesions are small , flat adenomas [Hurlestone 
2005 ; Lecomte 2005; East 2008 ; Stoffe l 2008] . In our study, fi ve compliant individuals 
developed CRC within one year of a previously normal screening colonoscopic 
examination (Chapter 4). Other studies have found that over 40% of interval CRCs 
detected by screening were diagnosed within 12 months of a normal screening 
colonoscopy [Engel 20 I 0]. Given the accelerated adenoma to carcinoma sequence in LS 
mutation carriers, these tumors were likely missed lesions. Chromoendoscopy 
[Hurlestone 2005 ; Lecomte 2005 ; East 2008], standard colonoscopy with intensive 
inspection (lasting > 20 minutes) [East 2008], narrow band imaging [Stoffel 2008] and 
autofluorescence endoscopy [Ramsoekh 20 1 OJ have all been shown to improve adenoma 
detection in LS patients. Future studies comparing each of these imaging techniques are 
needed to determine which is the most effective for CRC screening in LS. 
As was stated earlier, endometrial cancer screening has limited benefi t and is not 
performed in the general population for a number of reasons: low prevalence of disease; 
early detection of disease due to the occurrence of postmenopausal vaginal bleeding; and 
high survival rates [Schmeler 2008]. Similarly, screening for ovarian cancer is not 
perfo rmed due to the low prevalence of disease and the lack of good screening modalities 
for early cancer detection [Schmeler 2008; Buys 20 11]. However, due to the high 
gynecologic cancer risk in LS mutation carriers, gynecological cancer screening is 
recommended even though the benefi t of screening for this population has not been 
proven. 
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In chapter 5 we evaluated the impact of gynecological screening in female MSH2 
mutation carriers. We found that gynecological screening did not lead to earlier stage 
detection nor did it prevent interval gynecological cancers from occurring. The apparent 
inefficiency of gynecological screening in LS is likely due to both inadequate screening 
methods for early cancer detection [Schmeler 2008; Buys 2011] and the diagnosis of 
early stage endometrial and ovarian cancers in LS carriers regardless of screening status 
[Boks 2002; Crijnen 2005; Grindedal2010]. Given the lack of data on the efficacy of 
screening for endometrial and ovarian cancers and the demonstrated benefit of 
prophylactic gynecologic surgery, it has been proposed that prophylactic hysterectomy 
and bilateral salpingo-oophorectomy (BSO) be performed in female LS carriers who have 
completed child-bearing [Schmeler 2006; Manchanda 2009]. As we stated earlier, over 
70% of gynecological cancers likely would have been prevented in our study if women 
had underwent prophylactic hysterectomy and BSO after child-bearing. 
Outcomes regarding prophylactic gynecological surgery are not well studied. Differences 
in survival and disease-specific survival between women who undergo prophylactic 
gynecological surgery and those who do not are needed to assess the long-term effects of 
prophylactic surgery. There are also disadvantages to having prophylactic hysterectomy 
and BSO and these include surgical complications (most commonly, bleeding, infection, 
and injuries to the urinary tract and bowel) in a small number of individuals and 
premature menopause [Schmeler 2006]. Patients should be made fully aware of the 
limitations of endometrial and ovarian screening in LS and the possible surgical risks of 
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prophylactic surgery so that they can make an informed decision about the most 
appropriate management strategy for them. They must also take into consideration that at 
least 40% of female mutation carriers will never develop an endometrial cancer and 80-
90% may never develop ovarian cancer. Larger studies with longer follow-up are needed 
to fully evaluate the efficacy of gynecologic screening compared to prophylactic surgery 
in reducing gynecological cancer incidence and disease-specific mortality for female LS 
carriers. As well, evaluation of the factors influencing the decision to undergo 
prophylactic surgery and the impact of surgical menopause on quality of life, offer 
significant research opportunities. 
6.3 STUDY LIMITATIONS 
Bias of some degree will always be present in genetic epidemiological studies. It can 
affect all the major parts of an investigation, such as selection of subjects, performance of 
the maneuver, measurement of the outcome, data collection, data analysis, data 
interpretation, and even reporting the findings , leading to erroneous conclusions 
[Stuckless 2009]. These inherent limitations are often compounded by lack of power due 
to the reality of small sample sizes when studying genetic diseases. In chapters 3, 4 and 5, 
a brief summary of some of the potential limitations were addressed in the discussion 
sections of each respective chapter. I will expand on these limitations here. 
In chapter 3 we looked at the lifetime risks of colorectal, endometrial and other 
extracolonic cancers in a group of MSH2 mutation carriers. Kindreds were initially 
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identified by family history and met either the Amsterdam I or II criteria. However, as 
was stated earlier these criteria miss a substantial proportion of LS cases as they 
inherently select out a subgroup of families with a large number of CRC cases and a more 
severe phenotype. Smaller families with variable phenotypes are missed using these 
criteria and this can lead to ascertainment bias. This type of bias is introduced when the 
individuals selected for study are not representative of all cases in the population 
[Delgado-Rodriguez 2004; Stuckless 2009]. Therefore, our risk estimates in chapter 3 are 
likely to be overestimated due to use of multiple case families with earlier cancer onset 
and may not be generalizable to other LS carriers with an MSH2 mutation. 
Competing risks bias may have been an issue with this study as well. Often times in 
medical research, a patient may experience an event, other than the one of interest, which 
alters their risk of experiencing the actual event of interest. Such an event is referred to as 
a competing risk event [Satagopan 2004; Stuckless 2009]. MSH2 mutation carriers are at 
risk of developing a number of cancers, such as CRC, endometrial, ovarian and stomach 
cancer. In our study, for example, those who died early due to stomach cancer would no 
longer be at risk for CRC. In this situation, stomach cancer would be a competing risk 
event and it may cause the risk estimates for CRC to be overestimated. 
Another limitation relates to the fact that index cases were included in the study and this 
may have overestimated the lifetime cancer risk estimates . However, on the other hand, 
our penetrance estimates did not take into account screening status. It was likely that 
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some individuals were receiving colonoscopic screening, and as such, the risk estimates 
were likely to be underestimated . Screening status may also have been a potential 
confounder as the number of individuals receiving colonoscopic screening likely differed 
between the three mutation groups. Age and gender are also obvious potential 
confounders in practically a ll studies. No adjustment fo r these potenti al confounders was 
made when we compared the three specific mutations and this may have impacted our 
ri sk estimates. 
In chapters 4 and 5 we looked at the impact of colonoscopic screening and gynecological 
screening, respectively, on cancer incidence and overall survival. Most studies dealing 
with treatment effectiveness are best answered by means of randomized controlled trials. 
However, due to the high risk of cancer development in LS mutation carriers it is 
unethical to randoml y allocate mutation carriers to "screening" or "no screening", and as 
such, identification of an unbiased control group to compare outcomes of screening in LS 
families is difficult. As was stated earlier, our screening studies were limited by their 
retrospective nature and the use of an historical control group. However, due to time 
constraints and the lack of potential non-screened subjects in the present and future, the 
use of historical data was necessary. Historical controls are likely to have poorer 
outcomes due to lack of disease awareness in the past by both physicians and fam ily 
members. As well , possible confounders such as improvements in general nutrition, 
healthcare and management of advanced disease can impact these studies. This type of 
bias favors the screening intervention and may overestimate the benefit of screening. 
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Retrospective studies also rely partly on patient recollection of information and although 
efforts were made to confirm diagnoses, incomplete information for earlier records and 
the non-confirmation of early cancers may have impacted our study. 
Survivor bias, volunteer bias and compliance bias are also common in screening studies 
of this type. Survivor bias was a potential limitation in our screening studies as only those 
who were alive and disease-free could enter a screening program. Patients who died early 
of disease and did not receive screening likely differed in disease severity from those who 
received screening. Efforts were made to minimize the effect of this bias through our 
specific definition of controls in these studies. Volunteer bias, also referred to as self-
selection bias, is related to the fact that those who volunteer for study are likely different 
from those who refuse participation [Hartman 2002, Sica 2006, Stuckless 2009] . 
Volunteers tend to be better educated, healthier and lead better lifestyles than those who 
do not choose to enter screening. Both these biases can lead to an incorrect assumption 
that the screening intervention favorably affects outcome when in fact it may be that 
disease severity is responsible for the observed difference between the screened and non-
screened groups. These biases may have overestimated the effectiveness of screening in 
our studies. Compliance bias on the other hand can underestimate the effectiveness of 
screening. This bias occurs when differences in subject adherence to the planned 
screening protocol affects the study outcomes [Hartman 2002; Delgado-Rodriguez 2004; 
Stuckless 2009]. Patients who do not follow protocol guidelines may have worse 
outcomes than compliant patients leading to an apparent decrease in the effectiveness of 
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screening. This bias may also be compounded by physician compliance as well as the 
availability of screening procedures. If physicians do not provide appropriately scheduled 
appointments for patients or if wait times prevent timely access to screening procedures, 
the effectiveness of screening will again be underestimated. These issues likely played a 
role in our screening studies. 
As was stated earlier, longer follow-up is needed to fully evaluate the long-term 
outcomes of these screening studies. As well , due to small event rates for the 
gynecological screening study, our study may have lacked the power to detect a 
significant difference in outcome between the screened and non-screened groups if there 
had actually been one. Endometrial and ovarian cancers are biologically different and 
behave differently when it comes to morbidity and mortality associated wi th their 
development. Larger studies with more events are needed to evaluate the effectiveness of 
endometrial and ovarian cancer screening separately. 
Two other biases related to screening studies, but not addressed in chapters 4 and 5, are 
lead-time bias and length-time bias. Lead-time bias refers to the interval of time between 
diagnosis of cancer by screening and usual clinical detection due to symptoms. Lead-
time, therefore, is the amount of time that diagnosis was advanced as a result of screening 
[Herman 2002]. It can lead you to incorrectly conclude that screening prolongs life , when 
in fact, it simply extends the period of time for which cancer is observed. We tried to 
avoid introducing lead-time bias into our analyses by calculating survival from birth 
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rather than from diagnosis or enrolment in the study. Length-time bias refers to the fact 
that slower growing tumors (those with more favorable prognoses) exist for a longer 
period of time in the preclinical phase and are therefore more likely to be detected by 
screening. Faster growing tumors (more aggressive cancers), by contrast, exist for a 
shorter period of time in the preclinical phase and are more likely to be detected by 
symptoms between screening sessions [Herman 2002]. This bias can lead you to 
conclude that screening is beneficial when, in fact, observed differences in mortality rates 
resulted from detection of less severe disease in the screened group and diagnosis of more 
fatal disease in those with symptoms. 
6.4 BARRIERS TO SCREENING IN MSH2 MUTATION CARRIERS 
The effectiveness of colonoscopic screening in reducing the incidence of CRC and 
improving mortality in LS is well supported [Jarvinen 2000; Stupart 2009; Stuckless 
20 12] . However, despite this proven benefit, many high risk individuals are still not 
receiving the appropriate care, with adherence rates for colonoscopic screening varying 
widely [Hadley 2004; Halbert 2004; Bleiker 2005; Wagner 2005]. Although the benefit 
of gynecological screening in LS is controversial, screening guidelines do recommend 
transvaginal ultrasound (TVU), endometrial biopsy and CA 125 testing. As with 
colonoscopic screening, the uptake for these gynecological screening exams is 
suboptimal [Wagner 2005; Collins 2007; Hadley 2008]. 
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To improve adherence to screening recommendations, it is important to understand the 
barriers that prevent appropriate clinical management. In the general population, factors 
related to compliance with CRC screening include physician recommendations, perceived 
benefits from screening, age, having relatives with CRC, perceived susceptibi lity to CRC 
and coherence of screening [Collins 2005]. Studies of preventive behaviors in high-risk 
populations suggest that the main predictors of screening uptake are genetic test results 
and recommendations from health care providers [Hadley 2004; Halbert 2004; Collins 
2005]. Another study of high risk individuals found that barriers to colonoscopic 
screening included the embarrassing nature of the procedure itself, fear that a tumor 
would be detected during screening, the discomfort associated with the procedure and the 
absence of symptoms or complaints [Bleiker 2005]. In the United States, concerns about 
losing health insurance coverage and increased costs of health care have also been shown 
to be significant barriers to colon screening [Lynch 1993]. In regards to gynecological 
cancers, adherence to screening may be related to women's perceived risk of extracolonic 
cancers and physician's knowledge of the gynecological cancer risk and screening 
recommendations for female LS mutation carriers [Hadley 2008]. Belief in the efficacy 
of gynecological screening procedures and a family history of endometrial and/or ovarian 
cancer may also impact the uptake of gynecological screening [Collins 2007]. 
In chapter 4 we found that less than 50% of individuals in our study entered a 
colonoscopic screening program, and of those who did, less than 50% were compliant 
with colonoscopy every 1-2 years. Males were also less likely than females to enter a 
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colonoscopic screening program. In chapter 5, we found that less than one-third of 
females in our study had entered a gynecological screening program . Although many 
individuals in the non-screened groups were historical controls and were either deceased 
or had developed cancer prior to development of the screening program in 
Newfoundland, there were individuals w ho were not participating in the full scope of the 
program and/or not adhering to the recommended screening intervals. 
A recent study of these MSH2 mutation carriers looked at the factors influencing 
decisions about disease management post genetic testing [Watkins 201 1]. A lthough most 
participants seemed to be well-informed about LS, have accurate cancer risk perceptions 
and understand the benefits of regular screening, there were several personal, provider 
and health care system barriers to effective disease management. On a personal level, 
indiv idual's worries/concerns about potential test results/prophylactic interventions, 
frequency and type of screening required, preparation for and past experiences with 
screening examinations and scheduling issues, a ll increased the burden of disease 
management and sometimes became a deterrent to continuation or adherence. Practical 
issues such as financial status, fami ly responsibilities and employment history, also 
interfere with one's wi llingness and ability to follow recommended screening protocols. 
The perceived knowledge and skills of health care providers about the natural history of 
LS and their thoroughness of fami ly history taking and physical examinations were key 
factors impacting regular screening and disease management. Health care provider ' s 
famil iarity with their fam ily cancer history, completeness of medical care and quality of 
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communications improved adherence with screening and treatment protocols. Health care 
system challenges, such as gaining timely access to needed services, ineffective 
coordination of diagnostic, treatment and specialists' appointments, and lack of follow-
up, enhance the burden of disease and cause some individuals to distance themselves 
from the screening process. Recognition and prevention of the barriers to effective 
disease management is necessary for improved adherence to screening recommendations 
which in turn can lead to improved morbidity and mortality. 
6.5 BENEFIT OF THIS STUDY AND FUTURE DIRECTIONS 
Of the major cancers, CRC has the greatest opportunity for screening to have a major 
impact, both socially and economically. Colonoscopy can prevent cancer by removal of 
pre-malignant polyps or result in earlier stage diagnosis of CRC which is easier and less 
costly to treat. Colonoscopic screening in the general population has been shown to be 
cost-effective with savings in treatment outweighing the cost of screening [Ginsberg 
201 0]. An efficient screening program is necessary to improve the health outcomes of 
families at risk of CRC development. 
As was stated earlier, Newfoundland has the highest incidence of CRC in Canada and the 
highest incidence of familial CRC in the world. Of those with familial CRC, over 30% 
have high risk family histories and includes those with LS and familial colorectal cancer 
type X (FCCTX). These families have a high lifetime risk of developing CRC and require 
ongoing colonoscopic screening. Our research indicates the benefit of screening in these 
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high risk families with an MSH2 mutation and the need for adequate and timely 
colonoscopic examinations (Chapter 4). The high risk of gynecologic malignancy in LS 
also has important clinical implications. Our research indicates that gynecologic 
screening did not result in earlier gynecologic detection nor did it prevent gynecologic 
cancers from developing or ovarian cancer deaths from occurring (Chapter 5). For this 
high risk group of women, prophylactic hysterectomy with BSO may be the best method 
of endometrial and ovarian cancer prevention. 
Our research findings have helped in the development of a novel community-based 
screening program targeted at family members of incident CRC and gynecologic patients, 
stratified by cancer risk. Selectively targeting colonoscopic screening to those at high risk 
of developing CRC seems logical but no such program has previously existed. This 
health research project is the first of its type in Canada and pro-actively identifies 
families of CRC patients to provide a directed and coordinated screening program based 
on their level of cancer risk. 
All CRC patients in Newfoundland wi ll be offered this new community-based clinical 
screening service. A 3-generation pedigree will be developed for each CRC patient and 
family history of all cancers will be collected. A multi-step custom-designed algorithm 
which incorporates family history and other features , such as pathology manifestations 
and molecular testing, wi ll be used to identify families at increased risk of CRC. Those at 
highest risk will have their DNA tested against a panel of all CRC-associated mutations 
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currently identified in the Newfoundland population (currently 18 mutations specific for 
either LS, polyposis syndromes or MUTYH). Clinical screening guidelines for each level 
of risk and tumor pattern have been developed based on results of prior screening and 
barriers to adherence and effective screening have been identified so that the most 
efficient and targeted surveillance program for CRC and also gynecological cancers can 
be developed. 
The objective ofthis research screening program is to reduce the incidence and overall 
cost of managing CRC and gynecological cancer in Newfoundland. Families with the 
highest risk of developing CRC (families with well-documented mutations) wil l receive 
the most intensive screening protocols because the likelihood of preventing cancer is very 
high as evidenced by our study of MSH2 mutation carriers (Chapter 4). Those at lowest 
risk (no cancer history and no features characteristic of inherited cancers) wi ll receive the 
least intensive screening protocol because their likelihood of cancer detection wi ll be 
very low. For those at intermediate risk, the objective is to discover the genes and 
environmental factors that influence CRC development in this group, so that accurate risk 
assessment can be determined and the appropriate screening protocol can be initiated. 
Due to the high risk of gynecologic malignancy in cancer predisposition syndromes, 
identification of a high risk group can allow targeted prevention through prophylactic 
surgery. By targeting screening and management resources, cancers will be prevented 
and more lives will be saved, and thi s can have a large and immediate impact on both the 
social and economic burden of CRC and gynecologic cancer in Newfoundland. 
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This thesis is part of a larger project addressing the impact and evaluation of CRC 
screening on the burden of CRC in Newfoundland . Future work addressing the cost-
effectiveness of CRC screening in LS is planned and wi ll use our findings for MSH2 
mutation carriers discussed in chapter 4. Determination of the impact of screening in 
FCCTX families and other high risk families of unknown genetic etiology is also planned 
and will use the same methodology as that used in chapter 4 for LS. As well, the costs 
and outcomes ofthe community-based screening strategy in Newfoundland will be 
compared to Ontario ' s population screening program, where people with a famil y history 
of CRC can be referred by their doctor for colonoscopy. If our proactive targeted 
screening program leads to a more effective and economical use of screening resources 
compared to a generic population-based screening strategy, the screening intervention in 
Newfoundland may lead to improvements in the efficiency of surveil lance for CRC in all 
of Canada. 
142 
CHAPTER 7 
Summary & Recommendations 
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7.1 SUMMARY 
Lynch syndrome (LS) is the most common hereditary colorectal cancer (CRC) syndrome, 
however, lack of specific diagnostic features makes diagnosis of LS difficult. 
Identification of LS mutation carriers is very important as these individuals are at a 
substantially increased risk of CRC and endometrial cancer and also an increased risk of 
other extracolonic cancers. CRC develops at a young age and early detection is necessary 
for improved survival. Morbidity and mortality can be substantially improved in LS 
carriers due to early detection and prevention of CRCs by colonoscopic screening. 
Colonoscopic screening has been shown to reduce the incidence of CRC, delay the age of 
CRC onset and improve survival. The value of gynecological screening, however, is still 
controversial and does not appear to lead to earlier stage detection or prevention of 
gynecologic cancers. It has been proposed that prophylactic hysterectomy with bilateral 
salpingo-oophorectomy (BSO) may be the most appropriate management option for 
female LS carriers and should be performed after chi ldbearing is complete or at the time 
of CRC surgery for females who develop early onset CRC. Not all LS mutation carriers 
adhere to the recommended screening and treatment protocols and are therefore at a 
significantly increased risk of cancer-related morbidity and mortality. Identification of 
the barriers to screening and disease management are therefore necessary to ensure that 
individuals are receiving appropriate care. In conclusion, knowledge of the natural 
history and molecular genetics of LS are necessary for targeted screening and 
management strategies and ultimately cancer prevention, and emphasis should be placed 
upon barriers to effective disease management. 
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7.2 IMPLICATIONS 
..,.. Colonoscopic screening was shown to dramatically reduce cancer and cancer-related 
mortality in LS mutation carriers. Therefore, targeted screening programs aimed at those 
who are at high risk of CRC are necessary . 
..,.. Fewer men than women were participating in colonoscopic screening, and as such, 
special efforts are necessary to enroll these men . 
..,.. Compliance with the current screening recommendations of colonoscopy every 1-2 
years did not completely prevent the development of CRC. Future studies are needed to 
evaluate whether a screening interval of one year can further reduce the number of CRCs 
diagnosed in LS mutation carriers . 
..,.. Interval CRCs were detected within one year of a previously "normal" colonoscopic 
examination and this must question the quality of the colonoscopic exam. Future work is 
needed to determine the most effective colonoscopic imaging techniques for detection of 
precancerous lesions . 
..,.. Prophylactic hysterectomy and salpingo-oophorectomy for gynecological cancers in 
high risk populations has been shown to be cost-effective. In our study, gynecological 
screening did not result in earlier stage detection and interval cancers occurred, 
suggesting that gynecological screening may be ineffective for women with LS. 
145 
However, due to the limitations of our study and our small event rates, future studies are 
needed to address whether prophylactic surgery, as opposed to gynecological screening, 
should be recommended for these women. 
~A coordinated system of care and follow-up for screening and treatment of LS 
mutation carriers is necessary for appropriate disease management. 
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